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ABSTRACT 
 
 
Arsenic is a toxicant commonly found in water systems around the world. 
Evidence from epidemiological studies indicates that chronic arsenic exposure can 
result in cancer, central nervous system and sensory deficits, effects on development, 
and neuromuscular deficits. However, the molecular mechanism of arsenic’s toxicity 
remains largely unclear. In this study, both C2C12 mouse myoblast cells and mouse 
embryonic stem cells (mESCs) were used as models of arsenic mediated 
developmental toxicity in humans to investigate the effects of sodium arsenite on 
cellular differentiation. 
Results from our first and second studies indicate that exposure of 20nM 
sodium arsenite to C2C12 mouse myocyte cells results in delayed muscle 
differentiation due to a reduction myogenin expression. The repressed myogenin 
expression was due to a combination of abnormal DNA methylation and histone 
modifications on the myogenin promoter, repressed Igf-1 and Mef2 expression, and 
enhanced Ezh2 expression. In the third study, we examined arsenic’s effects earlier in 
development, using mouse P19 embryonic carcinoma cells as our model.  These 
results indicate that arsenic inhibits myogenesis and neurogenesis due to the reduction 
of essential myogenic and neurogenic transcription factors, such as Pax3, Myf5, 
MyoD, myogenin, neurogenin 1&2, and NeuroD. The reduction of these transcription 
factors was, in part, due to repressed Wnt/β-catenin signaling during early 
embryogenesis following arsenic exposure.  In conclusion, these results illustrate the 
mechanisms of how environmental realistic arsenic exposure impacts development. 
More importantly, this study gives us reasonable motivation to ask whether the 
 iii 
drinking water standard for arsenic is protective of fetal health.
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CHAPTER ONE 
 
INTRODUCTION 
 
BACKGROUND  
Arsenic is a naturally occurring mineral found in soil, bedrock, and water. It exists 
mainly in four valency states (-3, 0, +3, and +5), depending upon environmental 
conditions. The trivalent arsenic (As
+3
) and the pentavalent arsenate (As
+5
) are widely 
present in natural waters and are soluble over a wide range of pH conditions (Jones, 
2007). The primary route of exposure is through drinking water. Once ingested, inorganic 
arsenic is easily absorbed from the gastrointestinal tract, distributed throughout the body, 
often metabolized by methylation, and excreted primarily in urine (Benbrahim-Tallaa and 
Waalkes, 2007; Cohen et al., 2006; Reichard and Puga, 2010). 
Chronic arsenic poisoning is a global health problem affecting millions of people 
(McDonald et al., 2007; Medrano et al., 2010; Wang et al., 2009). Evidence from 
epidemiological studies indicate that chronic arsenic exposure in drinking water can 
result in cancer, central nervous system and sensory deficits, effects on development, and 
neuromuscular deficits (Andrew et al., 2007; Benbrahim-Tallaa and Waalkes, 2007; 
Kozul et al., 2009; Mohammad et al., 2009). Unfortunately, the mechanisms responsible 
these multiple adverse outcomes remain largely unclear and likely are multi-factorial. 
With increasing evidence showing that low arsenic concentrations increase cancer risk 
(Cohen et al., 2006), the WHO lowered the recommendation level to 10 ppb in 1993 
(WHO, 1993), whereaseas, the U.S. EPA reduced its drinking-water standard in regulated 
public water sources from 50 ppb to 10 ppb (0.67–0.13 μM) in 2006 (EPA, 2001).  
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ARSENIC METABOLISM 
Arsenic is primary metabolized in the liver, where arsenate (As
+5
) is bio-
transformed to arsenite (As
+3
) by arsenate reductase (EC 1.20.4.1). Arsenite (As
+3
) is then 
sequentially methylated to form methylarsonate (MMA
+5
) and dimethylarsinic acid 
(DMA
+5
) by arsenic methyltransferase (As3MT) or arsenite methyltransferase using S-
adenosylmethioine (SAM) as a methyl group donor (Fiskus et al., 2009; Reichard and 
Puga, 2010; M. Vahter, 2009). Due to the low toxicity of pentavalent methylated species, 
formation of methylated metabolites of inorganic arsenic has been regarded as a 
detoxification process for many years (Gebel, 2002; Zhou et al., 2008). However, recent 
findings of a high toxicity of trivalent methylated species have suggested that 
intermediates and products formed in this methylation pathway may be more reactive and 
toxic than inorganic arsenic (Cohen et al., 2006; Thomas et al., 2010; Tseng, 2009; Zhou 
et al., 2008).  
ARSENIC EXPOSURE RESULTS IN ALTERED DNA METHYLATION 
Recently, more attention has been focused on arsenic-induced DNA methylation. 
In many cells, arsenic undergoes enzymatic mono- and dimethylation, which is mediated 
by arsenic methyltransferase (As3MT) using S-adenosylmethioine (SAM) as a methyl 
group donor (Drobna et al., 2009; Jones, 2007; Reichard and Puga, 2010; Thomas et al., 
2010). However, SAM is also known as the universal methyl donor for the majority of 
methyltransferases that modify DNA, RNA, histones and other proteins, dictating 
replicational, transcriptional and translational fidelity, mismatch repair, chromatin 
modeling, epigenetic modifications and imprinting (Loenen, 2006). Since the 
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SAM/methyltransferase pathway for biotransformation of arsenic overlaps with the DNA 
methylation pathway, in which donation of methyl groups from SAM to cytosine 
produces 5-methylcytosine in DNA, one could hypothesize that the arsenic-induced 
adverse outcomes may be due to the imbalanced SAM pool within the organism. 
Additionally, aberrant induction of methyltransferases could lead to abnormal epigenetic 
controls on gene expression. To this end, studies have been conducted to show that 
overexpression of As3MT alters the transcriptional profiles upon arsenic exposure in 
human urothelial cells (Hester et al., 2009). Results from this microarray study indicate 
that “regulation of transcription” is the top 3rd most significant pathway. There were five 
significantly expressed genes in this pathway, all of which belong to heterochromatin 
protein 1 family in transcriptional silencing (Hester et al., 2009).  
In addition, Zhao and coworkers have shown that arsenic-induced global DNA 
hypomethylation occurred concurrently with aberrant gene expression and in the presence 
of reduced levels of SAM in nude mice (Zhao et al., 1997a). Moreover, Ramírez and 
coworkers have demonstrated that addition of SAM rescues the arsenic-induced 
alterations oin microtubule polymerization in HeLa cells (Ramírez et al., 2008). 
Individuals chronically exposed to arsenic in their drinking water had hypermethylation 
of the p53 and p16 promoters (Chanda et al., 2006), whereas whole genome 
hypermethylation in persons exposed to different levels of arsenic in drinking water has 
also been reported (Majumdar et al., 2009). Collectively, several cell culture and animal 
studies indicate that arsenic exposure results in both DNA hypomethylation and 
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hypermethylation, and thereby leading to aberrant gene expression (Reichard and Puga, 
2010; Salnikow and Zhitkovich, 2008).  
DNA methylation not only regulates gene expression, but also plays a role in 
muscle development. For example, Hu and coworkers have demonstrated that 
methylation of the α-smooth muscle actin (α-SMA) promoter inhibits α-SMA expression 
in mouse myofibroblast differentiation. The reduced α-SMA expression was due to the 
methylated CpGs block the binding of the essential transcription factor, transforming 
growth factor β (TGFβ), to its promoter regions (Hu et al., 2010). Nakatsuka et al. found 
that global DNA demethylation induces skeletal myogeneic differentiation of mouse 
dental pulp stem cells by up-regulating myogenin, MyoD1, and myosin heavy chain 
expression (Nakatsuka et al., 2010). This information suggests that arsenic-mediated 
DNA methylation could alter muscle development and myotube formation by altering 
muscle-specific transcription factors.  
ARSENIC EXPOSURE ALTERS HISTONE MARKS 
Arsenic exposure can modify histone acetylation and methylation patterns, 
leading to changes in gene expression. For example, arsenic-triggered phosphoacetylation 
of histone H3 in the c-fos and c-jun promoters have been identified in human diploid 
fibroblasts (Li, 2003). H3K9 dimethylation (H3K9me2) and H3K9 trimethylation 
(H3K9me3), both of which represent gene silencing marks, were induced at a global level 
in human lung carcinoma A549 cells and in normal human bronchial epithelial BEAS-2B 
cells upon exposure to low levels (0.1 μM) of arsenic (Zhou et al., 2008). Similarly, 
H3K4 trimethylation (H3K4 me3), which represents transcriptional activation, was 
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significantly induced at a global level in A549 cells and BEAS-2B cells upon exposure to 
0.1μM arsenic for 7 days. Interestingly, this epigenetic mark still remained elevated and 
inherited through cell division for 7 days following removal of arsenic (Zhou et al., 
2009). These two reports conclude that arsenic may induce histone remodeling to form 
either active or repressive chromatins within the same cell, indicating that arsenic plays a 
role in epigenetic control of gene expression.  
In addition to histone modification at a global level, arsenic-induced histone 
modification occurs in promoter regions of specific genes.  For example, arsenic can 
inhibit transcription mediated by all five steroid receptors (SRs) and two related class II 
receptors, the retinoic acid (RA) receptor and the thyroid hormone (TH) receptor, at 
environmentally relevant arsenic concentrations in cell culture and in animal models 
(Bodwell et al., 2006; Davey et al., 2007; Davey et al., 2008). The repressed steroid 
receptor-regulated gene transcription was due to the decrease in H3K18ac and H3R17me 
at glucocorticoid receptor-regulated promoters after treatment with arsenic (Barr et al., 
2009). These studies suggest that arsenic can act not only as a potent endocrine disruptor, 
but also a transcription factor that regulates histone remodeling. Moreover, in human 
UROtsa cells, arsenic induces Wnt5A transcription by enriching the permissive 
chromatin marks, H3K14ac and H3K4me2, and repressing the repressive chromatin 
marks, H3K27me3 and H3K9me2, in the Wnt5A promoter region (Jensen et al., 2009). 
Given this information, arsenic’s mechanism of action may also be mediated by 
epigenetic changes that lead to aberrant gene expression.  
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ARSENIC’S EFFECTS ON MUSCLE DEVELOPMENT 
In addition to the cancer endpoints, arsenic is also known as a developmental 
toxicant. In humans, arsenic can pass through the placental barrier, resulting in adverse 
developmental effects during pregnancy (Agusa et al., 2010; Concha et al., 1998; 
Markowski et al., 2011; Raqib et al., 2009; von Ehrenstein et al., 2006). Evidence from 
epidemiological studies indicates that arsenic exposure increases the risk of negative 
pregnancy outcomes (Table 1).  
 
Table 1.1: Epidemiological studies linking arsenic and adverse pregnancy outcomes 
As concentration Risk of adverse outcome Country  (reference) 
276-408 ppb 1.4X neonatal death increase Bangladesh (Rahan et al., 2007) 
>200 ppb 2.8X neonatal death increase India (von Ehrenstein et al., 2006) 
200 ppb 6X stillbirth increase India (von Ehrenstein et al., 2006) 
600 ppb 2X stillbirth increase China (Sen and Chaudhuri, 2008) 
>90 ppb -30g birth weight reduction Taiwan (Yang et al., 2003) 
40 ppb -57g birth weight reduction Chile (Hopenhayn et al., 2003) 
 
For example, studies in India find a 2.8-fold increased risk of neonatal death and a 
6-fold increased risk of stillbirth in women exposed to > 200 ppb of arsenic through 
drinking water compared to those that drank uncontaminated water (von Ehrenstein et al., 
2006). In Taiwan and Chile, average birth weight was lower in regions with increased 
arsenic in drinking water (Hopenhayn et al., 2003; Yang et al., 2003). Even an outcome 
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as minor as lowered birth weight can have physiological consequences later in life.  For 
example, low-birth-weight piglets form reduced numbers of muscle fibers during prenatal 
myogenesis, and therefore, these animals do not exhibit postnatal “catch-up ” growth 
(Rehfeldt and Kuhn, 2006). Arsenic’s effects on muscle differentiation may play an 
important role and result in adverse developmental outcomes. 
To date, results from in vitro and in vivo studies have shown that arsenic-exposure 
has adverse effects on muscle differentiation. In fish models, the offspring of 
mummichogs (Fundulus heteroclitus) whose parents were exposed to arsenic displayed 
curved/stunted tails, which was correlated to the induction of myosin light chain, type II 
keratin, tropomyosin, and parvalbumin in the hatchlings (Gonzalez et al., 2006). 
Zebrafish embryos exposed to arsenic, albeit at high concentrations, had increased dorsal 
curvature and flat heads, and reduced heart rates. The morphological malformations in 
the heart were due to the reduced myosin heavy chains protein expression in the ventricle 
and atrium (Li et al., 2009). In mammalian systems, arsenic exposure to mouse C2C12 
myoblasts resulted in delayed muscle differentiation into myotubes (Steffens et al., 2011). 
Rodent models indicate that arsenic suppresses the regeneration of injured muscles (Yen 
et al., 2010), and disrupts the smooth muscle integrity around the blood vessels in the 
thoracic aorta (Lim et al., 2011). In addition, mice exposed to arsenic in utero had 
increased smooth muscle actin protein expression in their lungs, which altered pulmonary 
structure and function (Lantz et al., 2009). Collectively, these results suggest that arsenic 
acts as a developmental toxicant by affecting the development of the musculature. 
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However, the molecular mechanisms behind the arsenic-mediated adverse effects on 
muscle development remain largely unknown.   
Skeletal muscle development in vertebrates occurs in several defined steps. 
Mesoderm-derived precursor cells become committed to the myogenic lineage and 
develop into myoblasts, which subsequently fuse to form myotubes. Later, myotubes 
mature into multinucleated highly specialized muscle fibres that show cross striation 
(Brandsaberi, 2005; Darabi and Perlingeiro, 2008). During myogenesis, several myogenic 
transcription factors are required to regulate muscle differentiation at different stages. For 
example, Pax3 is needed so that embryonic progenitor cells can enter into the myogenic 
program (Messina and Cossu, 2009; Otto et al., 2006; Ridgeway and Skerjanc, 2001). 
Expression of muscle regulatory factors (MRFs), such as Myf5, Mrf4, and MyoD, are 
required for myoblast determination, while myogenin is needed for terminal 
differentiation (Carvajal and Rigby, 2010; Gianakopoulos et al., 2011; Yokoyama and 
Asahara, 2011). Aside from muscle regulatory factors, other molecules also regulate the 
development of skeletal muscle. For example, myocyte enhancer factor 2 (MEF2) can 
promote muscle differentiation by directly up-regulating myogenin expression (Lu et al., 
2000; Molkentin et al., 1995; Ohkawa et al., 2006). Signaling molecules, such as insulin-
like growth factor 1 (IGF-1) and myostatin regulate myogenin expression via the 
PI3K/AKT pathway during skeletal muscle development (Alzhanov et al., 2010; Artaza 
et al., 2002; Yang et al., 2007). Moreover, other chromatin-modifying enzymes, such as 
the polycomb Ezh2 methyltransferase (Ezh2) and G9a histone methyltransferase, have 
been reported to play a role in the repression of muscle differentiation by epigenetically 
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repressing myogenic transcription factors (Caretti et al., 2004; Davis et al., 2006; Juanet 
al., 2009). Given this information, whether arsenic could alter these muscle-specific 
regulatory factors and thereby leading to the reduced muscle differentiation will be 
examined in this study.   
ARSENIC’S EFFECTS ON NEURONAL DIFFERENTIATION 
Arsenic can cross the blood-brain barrier (Au et al., 2008; Jin et al., 2006; Kiguchi 
et al., 2010; Knipp et al., 2007; Xi et al., 2010) and accumulate in the developing brain, 
thereby leading to neurotoxicological effects on the developing nervous system. In 1955, 
a mass poisoning due to arsenic contaminated infant formula in Japan caused 130 infant 
deaths out of 12,000 suspected victims (Hamamoto, 1955; Koyama, 1955). The follow-
up study on more than 600 surviving victims indicates that these survivors, now in theirs 
50s, have suffered from mental retardation and neurological diseases (Dakeishi et al., 
2006). In addition, other epidemiological studies have shown that arsenic exposure 
during early life stages correlates with adverse neurotoxicological effects (Table 2). For 
instance, arsenic contamination in drinking water has been linked to neurological 
diseases, such as hearing losses, mental retardation, refraction anomaly, and lower 
intelligence quotient score (Bencko et al., 1977; Calderon et al., 2001; Tsai et al., 2003).  
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Table 1.2: Epidemiological studies linking arsenic and adverse neurotoxicological 
effects 
As concentration Risk of adverse outcome Country  (reference) 
900 ppb Hearing losses Czech Republic 
(Bencko and Symon, 1997)  
540-590 ppb Refraction anomaly, hearing losses, 
and IQ <85 
Japan 
(Dakeishi et al., 2006) 
 130 ppb Altered pattern memory and 
switching attention 
Taiwan 
(Tsai et al., 2003) 
40 ppb  
 
Lower full-scale and verbal IQ Mexico 
(Calderon et al., 2001) 
20 ppb  
 
Lower full-scale and verbal IQ USA 
(Wright et al., 2006) 
 
 
Indeed, arsenic exposure can repress neuronal differentiation.  For example, 
arsenic exposure induces apoptosis in primary cultures of rat cerebellar neurons through 
the induced nuclear fragmentation and condensation in cerebellar neurons (Namgung and 
Xia, 2001). In neuroblastoma cells, arsenic exposure inhibits neuronal proliferation, 
differentiation, and neurite outgrowth (Cheung et al., 2007; Wang et al., 2010). 
Additionally, Piao et al. have observed that arsenic exposure in drinking water induces 
several histopathological changes in the mouse brain, including nuclear vacuolation, and 
neurite loss in the cerebral and cerebellum cortex (Piao et al., 2005). Moreover, rats 
exposed in utero to arsenic via the dams’ drinking water showed the loss of activity in the 
locomotion and in the movement of limbs (Chattopadhyay et al., 2002; Rodr  guez et al., 
2002). Taken together, these studies indicate that arsenic exposure also has adverse 
effects on neuronal development.  
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Neuronal development and regulation differs depending on the specific neuronal 
subpopulation. In sensory neuron lineage, for example, the Wnt/ β-catenin signaling 
pathway commits neuronal crest-derived progenitor cells to sensory neural precursors 
(Howard, 2005). Pax3, neurogenin1, and neurogenin 2 then are required for neuroblast 
determination (Cau et al., 2002; Kim et al., 2011; Ma et al., 1999). Later, the expression 
of NeuroD, which is regulated by neurogenin 1 and neurogenin 2, promotes the terminal 
differentiation of sensory neurons (Cherry et al., 2011; Howard, 2005; Ohsawa and 
Kageyama, 2008). Therefore, whether arsenic exposure alters the expression of neuron-
specific transcription factors will be examined in this study.   
EMBRYOTOXICITY OF ARSENIC 
Laboratory studies have suggested negative effects of arsenic on early embryonic 
development. For example, zebrafish embryos exposed to 0.5mM arsenic displayed 
reduced survival, delayed hatching, and retarded growth (Li et al., 2009). In rodents, 
arsenic exposure caused total embryo lethality, major deformities, complete failure to 
undergo zona lysis, and significantly higher number of blastomere cells with fragmented 
DNA in embryos at concentrations of 500 to 750 nM (Unis et al., 2009). In addition, 
Petrick and coworkers have shown in utero arsenic exposure through maternal drinking 
water causes altered gene and protein expression, such as β-catenin, GSK3 beta, Tcf /Lef, 
integrin b3, and interleukin-4 in the developing lung. The reporter analysis indicates that 
β-catenin signaling is a likely site of action (Petrick et al., 2009). In utero arsenic 
exposure also has transplacental carcinogenic effects on newborn mice. For example, 
male offspring exposed to 85 ppm arsenic in utero had increases in adrenal cortical 
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adenoma and hepatocellular carcinoma incidence during adulthood, while female 
offspring developed lung carcinoma and ovarian tumors (Waalkes et al., 2007). 
Moreover, several other studies have observed alterations in DNA methylation and a 
complex set of aberrant gene expression in newborn mice whose parents were exposed to 
85ppm arsenic during pregnancy (Xie et al., 2007). 
To date, embryonic stem cells are one of the most promising models for the 
evaluation of developmental toxicity (Adler et al., 2008; Bal-Price et al., 2010) because 
they are capable of differentiating into every specialized cell type (Angello et al., 1997; 
Vanderheyden and Defize, 2003; Wobus and Guan, 1998). To this end, results from 
embryotoxicity hazard assessment, using mouse stem cells, classified arsenic as an 
embryotoxic metal with an IC50 ranging from 0.7 to 1.3μM (Stummann et al., 2008).  In 
human stem cells, Flora and Mehta have demonstrated that 76nM arsenic not only altered 
the pluripotency of stem cells but also caused a significant down regulation of genes 
indicative of all the three germ layers (Flora and Mehta, 2009). For instance, the 
expression of GATA-4, which is an indicative marker of cardiac muscle in endoderm 
lineage, was significantly repressed upon exposure to 1ppm arsenic (Flora and Mehta, 
2009). Moreover, Tokar and coworkers have demonstrated that 5μM arsenic directly 
transforms normal human prostate epithelial stem cells into an aggressive pluripotent 
cancer stem cell phenotype (Tokar et al., 2010). Collectively, these and other results 
suggest that arsenic could act as a developmental toxicant and affect the development of 
the reproductive system, nervous system, and skeletal system.  
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WNT/ β -CATENIN SIGNALING IN EMBRYOGENESIS  
Wnt molecules are cysteine-rich secreted glycoproteins that can locally interact 
with the Frizzled (FZD) family of receptors on the plasma membrane. Wnt signaling can 
be classified as canonical (β-catenin dependent) or non-canonical (β-catenin independent) 
(Geetha-Loganathan et al., 2008; Ling et al., 2009; Liu et al., 2008). In silenced canonical 
Wnt signaling, β-catenin proteins are degraded through proteolysis in cytosol in the 
absence of Wnt ligands. When cells receive Wnt signals, the Wnt molecule can bind to a 
frizzled (Fz) receptor to activate canonical Wnt signaling.  This then inhibits β-catenin 
degradation and stabilizes β-catenin in the cytosol.  The accumulated cytoplasmic β-
catenin can be subsequently translocated into nucleus, where it forms a complex with 
Tcf/Lcf transcription factors to initiate the transcription of Wnt-target genes (Geetha-
Loganathan et al., 2008; MacDonald et al., 2009; Novak and Dedhar, 1999).  
During early vertebrate development, the canonical Wnt/ β-catenin signaling 
pathway plays an important role in developmental process, such as somite formation and 
neural crest development (Borello et al., 2006; Burstyn-Cohen et al., 2004; Geetha-
Loganathan et al., 2008; Huelsken and Birchmeier, 2001; Schmidt et al., 2008). In 
embryonic stem cells, β-catenin regulates self-renewal and cell fate decisions (Ling et al., 
2009; Liu et al., 2008; Lyashenko et al., 2011). For instance, Lyashenko et al. have used 
a β-catenin-deficient mouse stem cell line to demonstrate that self-renewal is maintained 
in the absence of β-catenin, whereas wild-type stem cells form all three germ layer 
(Lyashenko et al., 2011). It has also been shown that β-catenin can trigger cells to 
differentiate into a myocyte lineage in P19 mouse embryonal carcinoma cells 
 14 
(Petropoulos and Skerjanc, 2002) and cause neuronal differentiation in the WWE6 ES 
cells (Otero et al., 2004) without any chemical treatments. Therefore, these studies 
suggest that β-catenin is required for early embryonic development. To this end, it is 
worthy to understand the effects of arsenic on Wnt/ β-catenin signaling using stem cell 
models. Altered Wnt/ β-catenin signaling due to arsenic-exposure may provide insight 
into the mechanisms behind its toxicity in earlier developmental stages.     
OBJECTIVES OF THIS STUDY 
Our preliminary results indicate that 20 nM arsenic delays muscle cells 
differentiation and suppresses the expression of myogenin. However, the molecular 
mechanisms of arsenic’s toxicity remain largely unknown. Therefore, the goal of this 
study was to investigate the effects of sodium arsenite on cellular differentiation using 
both C2C12 mouse myoblast cells and mouse embryonic stem cells (mESCs) as models. 
The specific objectives include: 
1. to determine the epigenetic mechanisms by which arsenic exposure alters the 
expression of myogenin 
2. to identify potential regulatory mechanisms that regulate myogenin expression 
upon arsenic exposure 
3. to investigate whether the arsenic exposure delays the differentiation of mouse 
embryonic stem cells (mESCs) into muscles and neurons through alterations 
in the Wnt/ β-catenin signaling pathway 
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Accomplishing these objectives should provide insight into how arsenic represses 
muscle differentiation through abnormal epigenetic mechanisms and changes in 
transcription factor expression.  Additionally, arsenic’s effects on the Wnt/ β-catenin 
signaling pathway during early embryogenesis and its consequences for cellular 
differentiation will be determined using a mouse stem cell model.  
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Abstract 
Epidemiological studies have correlated arsenic exposure with cancer, skin 
diseases, and adverse developmental outcomes such as spontaneous abortions, neonatal 
mortality, low birth weight, and delays in the use of musculature. The current study used 
C2C12 mouse myoblast cells to examine whether low concentrations of arsenic could 
alter their differentiation into myotubes, indicating that arsenic can act as a 
developmental toxicant.  Myoblast cells were exposed to 20nM sodium arsenite, allowed 
to differentiate into myotubes, and expression of the muscle-specific transcription factor 
myogenin, along with the expression of tropomyosin, suppressor of cytokine signaling 3 
(Socs3), prostaglandin I2 synthesis (Ptgis), and myocyte enhancer 2 (Mef2) were 
investigated using QPCR and immunofluorescence.  Exposing C2C12 cells to 20nM 
sodium arsenite delayed the differentiation process, as evidenced by a significant 
reduction in the number of multinucleated myotubes, a decrease in myogenin mRNA 
expression, and a decrease in the total number of nuclei expressing myogenin protein. 
The expression of mRNA involved in myotube formation, such as Ptgis and Mef2 mRNA, 
was also significantly reduced by 1.6-fold and 4-fold during differentiation.  This was 
confirmed by immunofluorescence for Mef2, which showed a 2.6 fold reduction in 
nuclear translocation. Changes in methylation patterns in the promoter region of 
myogenin (-473 to +90) were examined by methylation-specific PCR and bisulfite 
genomic sequencing. Hypermethylated CpGs were found at -236bp and -126bp, whereas 
hypomeththylated CpGs were found at -207bp in arsenic exposed cells. Arsenic exposure 
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delays myotube differentiation and represses myogenin expression in part by altering 
DNA methylation in the myogenin promoter. 
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Introduction 
Arsenic is present in drinking water systems around the world as both a natural 
element and as a contaminant due to normal geological processes and human 
disturbances (Mandal and Suzuki, 2002).  Epidemiological studies indicate that long-term 
exposure to arsenic can result in adult-onset diseases, such as cancer, cardiovascular 
disease, diabetes, and skin lesions (Guha Mazumder, 2008; Mink et al., 2009; Platanias, 
2009; Schuhmacher-Wolz et al., 2009; States et al., 2009). Although most studies have 
focused on outcomes such as cancer, epidemiological evidence indicates that arsenic can 
also act as a developmental toxicant (Cherry et al., 2008; Hopenhayn-Rich et al., 2000; 
Milton et al., 2005; Rahman et al., 2007; Rahman et al., 2009). Arsenic has been shown 
to cross the placental barrier in humans and rodents (Concha et al., 1998; Jin et al., 2010; 
Xie et al., 2007), and studies in rodent models have shown that dams exposed to arsenic 
in their drinking water had an increase in aborted fetuses, while their offspring had low 
birth weight and changes in locomotor activity (Ahmad et al., 2001; He et al., 2007; Jinet 
al., 2005; Waalkes et al., 2004; Waalkes et al., 2003).   
Moreover, in utero arsenic exposure also alters muscle function and muscle-
related protein expression in the offspring.  For example, arsenic exposure in utero 
reduced the ability of smooth muscle to relax and resulted in changes in the vascular 
matrix by decreasing the amounts of collegen and elastin (Hays et al., 2008; Srivastava et 
al., 2007).  In fish species, such as killifish, parental arsenic exposure increased 
tropomyosin and myosin light chain 2 expression in the offspring (Gonzalez et al., 2006). 
Zebrafish exposed to arsenic during embryogenesis showed altered heart development, 
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and their somite and neuromuscular patterning correlated to altered cell proliferation and 
genomic DNA methylation (Li et al., 2009). Alterations in muscular regulatory factors 
during zebrafish somitogenesis resulted in impaired development of fast skeletal muscle 
(Tilton and Tanguay, 2008). Additionally, arsenic exposure to frogs prior to 
metamorphosis resulted in reductions in swimming ability (Chen et al., 2009).   
Skeletal muscle development occurs in several defined steps. Mesoderm-derived 
precursor cells become committed to the myogenic lineage and develop into myoblasts, 
which subsequently fuse to form myotubes. Later, myotubes mature into multinucleated 
highly specialized muscle fibers that show cross striation (reviewed in Brand-Saberi, 
2005; Darabi et al., 2008). During muscle differentiation, myogenin is the key 
transcription factor that initiates the conversion of a skeletal muscle myoblast to a 
myotube (Buckingham et al., 2003). Recently, it has been reported that myogenin 
regulates several genes during muscle differentiation. For example, both in vitro and in 
vivo studies in mice indicate that conditional knockout of myogenin represses muscle 
stem cell differentiation along with reducing the expression of genes that are involved in 
myogenesis, including prostaglandin I2 synthesis (Ptgis), suppressor of cytokine 
signaling 3 (Socs3), and myocyte enhancer 2 (Mef2) (Meadows et al., 2008).  
To date, it has been shown that methylation status on the myogenin promoter 
plays an important role in activation of myogenin. For example, in undifferentiated 
C2C12 myoblast cells, the myogenin promoter is maintained in a completely methylated 
status, which results in little myogenin expression. However, during differentiation, the 
promoter region undergoes demethylation within 48 hours and subsequently recruits its 
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transcription factors, such as MyoD, to initiate transcription (Fusoa et al., 2001; Lucarelli 
et al., 2001; Sartorelli and Caretti, 2005). Interestingly, when S-adenosylmethionine 
(SAM) is administered to C2C12 cells, it can repress expression of myogenin by delaying 
the demethylation of the 5’-flanking region on the myogenin gene (Fusoa et al., 2001; 
Lucarelli et al., 2001).  
In many cells, arsenic undergoes enzymatic mono- and dimethylation, which is 
mediated by arsenic methyltransferase (As3MT) using SAM as a methyl group donor 
(Liu et al., 2007; Tsai et al., 2009; Vahter et al., 2007). However, SAM is also the 
universal methyl donor for the majority of methyltransferases that modify DNA, RNA, 
histones and other proteins, which dictates replication, transcription and translation 
fidelity, mismatch repair, chromatin modeling, epigenetic modifications and imprinting 
(Loenen, 2006). Since the SAM/methyltransferase pathway for biotransformation of 
arsenic overlaps with the DNA methylation pathway, one could hypothesize that the 
arsenic-induced adverse outcomes may be due to the imbalanced SAM pool within the 
organism.  To this end, Zhao et al. have shown that arsenic induced global DNA 
hypomethylation occurred concurrently with aberrant gene expression and in the presence 
of reduced levels of SAM in mice (Zhao et al., 1997). Individuals chronically exposed to 
arsenic in their drinking water had hypermethylation on the promoters of p53 and p16 
(Chanda et al., 2006), whereas whole genome hypermethylation in persons exposed to 
arsenic in drinking water has also been reported (Majumdar et al., 2009). Collectively, 
studies indicate that arsenic exposure results in both DNA hypomethylation and 
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hypermethylation, leading to aberrant gene expression (Benbrahim-Tallaa and Waalkes, 
2008; Salnikow and Zhitkovich, 2008). 
The objectives of the present study were to: 1) determine whether a low 
concentration of sodium arsenite delayed the differentiation of C2C12 cells from 
myoblasts to myotubes by repressing the transcription factor myogenin; 2) examine 
whether the reduction in myogenin would impact the expression of myogenic proteins 
involved in contraction and myotubes formation; and 3) determine whether DNA 
methylation patterns on the myogenin promoter were altered to better understand the 
molecular mechanism of arsenic. 
Methods 
Arsenic exposure and quantification of multinucleated myocytes.  
The mouse myoblast C2C12 cell line (ATCC, Manassas, VA) was  seeded at 860 
cells/well in 6 well plates, and cultured with or without 20nm sodium arsenite in DMEM 
supplemented with 10% fetal bovine serum, 1% L-glutamine and 1% 
penicillin/streptomycin (growth media) at 37°C in a humidified incubator containing 5% 
CO2. To differentiate the cells, the medium was replaced with DMEM supplemented with 
2% horse serum, 1% L-glutamine and 1% penicillin/streptomycin (differentiation media) 
(Kubo, 1991) with or without 20nM arsenic.   
Myotube formation was examined on differentiation days 0, 1, 2, 3, and 4 (n=6 
per group per day by fixing the cells in methanol and incubating them in Giemsa stain.  
Cells were considered to be multinucleated if they contained 3 or more nuclei (Duan and 
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Gallagher, 2009).  A multinucleation index was calculated by dividing the total number 
of cells by the number cells containing >3 nuclei.   
QPCR.   
C2C12 cells were plated at 5000 cells/100mm dish in either growth medium or in 
growth medium containing 20nM sodium arsenite, and on the fourth day, differentiation 
medium alone or differentiation medium containing 20nM sodium arsenite was added. 
Cells were harvested on days 0 or 4 (n=4 per group per day) and RNA was extracted 
using TRIreagent (Sigma-Aldrich, St. Louis, MO). RNA (2µg) was reverse transcribed 
into cDNA, and the expression of myogenin, myosin light chain 2, tropomyosin, 
prostaglandin I2 synthase (Ptgis), suppressor of cytokine signaling 3 (Socs3), and 
myocyte enhancer factor 2 (Mef2c) was quantified by QPCR using SybrGreen 
(SABiosciences, Frederick, MD) and the appropriate primers (Table 2. 1). Samples were 
run in triplicate and the entire experiment was repeated at least twice.  The cycle 
threshold values (Ct) were converted into number of molecules per 100ng cDNA using 
known concentrations of the specific gene product, and then normalized using GAPDH. 
Cellular expression and localization of myogenin, tropomyosin, and Mef2c.   
C2C12 cells were seeded in Lab-tek II eight well coverglass slides (Nunc) at a 
concentration of 100 cells/well.  Cells were cultured with or without 20nM sodium 
arsenite as described above and examined for specific protein expression on 
differentiation days 0, 1, 2, 3, and 4 (n=8 chambers per protein per group per day). Cells 
were blocked in 1% bovine serum albumin, 0.1% Triton-X100 in PBS, and incubated 
with the appropriate primary antibody for 1 hour (myogenin: 1:100 dilution, Imgenex; 
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tropomyosin: 1:50 dilution, Santa Cruz Biotechnologies; Mef2: 1:50 dilution, Santa 
Carlsbad, CA) was incubated with the cells, which were counterstained with DAPI 
(Invitrogen.  Cells were examined by conventional immunofluorescence on a Ti Eclipse 
Inverted Microscope (Nikon, Melville, NY). Myogenin and Mef2c expression was 
quantified by determining the percentage of nuclei expressing each protein. Tropomyosin 
expression was quantified by determining the mean pixel intensities in individual cells by 
examining 4 fields per slide. 
Bisulfite genomic sequencing of the myogenin promoter.   
Bisulfite genomic sequencing PCR was performed using specific primer sets to 
amplify nucleotides −473 to +90 relative to the transcription start site (TSS) of myogenin 
(Table 2.1). C2C12 cells were seeded at 1.5x10
5
/150mm tissue culture plate and were 
cultured with or without 20nM sodium arsenite as described above.  Genomic DNA was 
extracted on differentiation day 2 using Qiagen’s Genomic DNA extraction kit (Valenic, 
CA; n=3 plates per group).  Sodium bisulfite treatment of the DNA was performed using 
the EpiTect Kit (Qiagen). The BS-PCR reaction was performed for 40 cycles and the 
products were cloned into the pCR2.1 vector (Invitrogen) and transformed into Top10 
chemically competent E. coli (Invitrogen).  Twenty to thirty randomly selected clones 
from the control and arsenic-exposed group were sequenced with the M13 reverse primer 
to determine whether each one of the 12 CpG sites was methylated or not. A chi-square 
test was used to determine statistical significance between control and arsenic-exposed 
cells. 
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Results 
Arsenic delays C2C12 muscle cell differentiation 
Initial cell viability assays demonstrated that the LC50 of sodium arsenite in 
C2C12 cells was 5μM (data not shown), so we used a 250-fold lower concentration to 
determine whether arsenic caused a delay in C2C12 cell differentiation. Cells were 
cultured either with or without 20nM sodium arsenite in growth media for 3 days and 
then in differentiation medium for up to 4 days. Both control and arsenic-exposed cells 
appeared predominantly as myoblasts during culture in growth medium (Fig. 2.1A-B). 
After the switch to differentiation medium, myotube formation was reduced in the arsenic 
exposed cells compared to the controls (Fig. 2.1C-D). Quantifying the number of 
multinucleated cells as an indicator of myotube formation indicated that the number of 
multinucleated cells was significantly reduced between 1.5- and 2.9-fold in the cells 
exposed to arsenic (Fig. 2.1E).  
Myogenin transcript and nuclear localization is reduced during arsenic exposure 
Since arsenic appeared to delay C2C12 cell differentiation and multinucleation, 
the expression of myogenin, the transcription factor that initiates the differentiation of a 
myoblast to a myotubes, was examined. When C2C12 cells were cultured in growth 
medium, there was very low expression of myogenin mRNA in both control and arsenic-
exposed cells. However, by day 2 of differentiation, myogenin transcript was 
significantly reduced 7-fold in the arsenic-exposed cells, and on day 4, myogenin RNA 
levels were still reduced by 4.1-fold in the arsenic-exposed cells compared to control 
cells (Fig. 2.2 H). The reduced levels of RNA also correspond with alterations in 
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myogenin nuclear translocation.  In growth medium, myogenin is localized in the 
cytoplasm in both control and arsenic-treated cells (Fig. 2.2 A and D). After 2 days of 
differentiation, myogenin in the control cells shifts to the nuclei (Fig. 2.2 B and E), as the 
number of nuclei expressing myogenin was significantly reduced in the arsenic-exposed 
C2C12 cells by 1.6-fold (Fig 2.2 G).  The reduced expression of myogenin is likely 
causing the delay in differentiation in arsenic-exposed cells.    
Altered Cellular Expression and Localization of Muscle Proteins 
Since myogenin expression was reduced after arsenic exposure, we next 
determined whether this would lead to alterations in myogenic proteins.  The expression 
of tropomyosin mRNA, a part of the contractile apparatus, was unchanged after arsenic 
exposure (Fig. 2.3 A).  Its protein expression, as examined by immunofluorescence, was 
also not altered (data not shown). Similarly, Socs3, a protein that has been reported to 
induce the differentiation of myoblasts (Spangenburg, 2005), was also not changed after 
exposure to arsenic (Fig. 2.3 C). However, the RNA expression of Mef2c, a transcription 
factor that is expressed during late myogenesis (McDermott et al., 1993) that appears to 
control myofiber subtype (Potthoff et al., 2007b; Wu et al., 2000), was reduced by 4-fold 
after arsenic exposure (Fig. 3B). Additionally, Ptgis, which is thought to be involved in 
myoblast fusion (Bondesen et al., 2007; Prisk and Huard, 2003), was also significantly 
reduced by 1.6-fold in cells treated with 20nM arsenic (Fig. 2.3 D). Immunofluorescence 
corroborated the QPCR results for Mef2c, showing a reduction in nuclear translocation 
by 2 to 2.7-fold in the arsenic treated cells (Fig. 2.4 G).  
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Changes in Myogenin Promoter Methylation 
To investigate one of the potential mechanisms responsible for the changes in 
myogenin expression, we examined methylation patterns on the myogenin promoter.  
Bisulfite sequencing PCR was performed to amplify the nucleotides -473 to + 90 relative 
to the transcription start site (TSS) of myogenin, which contains a total of 12CpG sites 
(Fig. 2.5A). Chi-square analysis indicated that hypermethylated CpGs were found at CpG 
No. 3 and 8 (-236 and -126, respectively), whereas hypomethylated CpGs were found at 
CpG No. 7 (-207) in arsenic exposed cells (Fig. 2.5 B and C). This increase in methylated 
CpG sites on the myogenin promoter may be, in part, responsible for the reduction in 
myogenin mRNA and nuclear localization in arsenic-exposed C2C12 cells.  
Discussion 
These results illustrate that 20nM sodium arsenite can alter myoblast 
differentiation by reducing the expression of the transcription factors myogenin and 
Mef2c, which is likely due to changes in promoter methylation patterns. To our 
knowledge, this is the first study that has examined the affects of low nanomolar arsenic 
concentrations and its effect on the development of skeletal muscle cells.  Previous 
studies have used much higher arsenic concentrations, ranging from 0.1 – 267μM, when 
examining cardiac, skeletal, and smooth muscle development in vivo or in vitro (He et al., 
2007; Lantz et al., 2008; Li et al., 2009; Yen et al., 2010). For example, when zebrafish 
embryos were exposed to 2mM arsenic, the embryos had malformations of the 
musculature like dorsal curvature and improper heart development (Li et al., 2009). In 
utero and postnatal arsenic exposure of 100ppb in mice increased the amount of smooth 
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muscle mass and actin in the lung (Lantz et al., 2008). Additionally, when pregnant mice 
ingested drinking water containing 20ppm or higher sodium arsenite, there was a 
decrease in their fecundity, and if offspring were produced, their placenta experienced 
defective formation of blood vessels (He et al., 2007). All these studies provide evidence 
that arsenic can act as a developmental toxicant. 
During the development of skeletal muscle, myogenin is the transcription factor 
that regulates the differentiation of a myoblast to a myotubes. Myogenin knockout mice 
die shortly after birth due to malformation of skeletal muscles and lack of diaphragm 
formation (Hasty et al., 1993). In the present study, myogenin mRNA was reduced in the 
arsenic-treated cells during days 2, 3 and 4 of differentiation A recently published study 
also saw reductions in myogenin after exposure of C2C12 cells to arsenic (Yen et al., 
2010), although the arsenic levels used in that study were an order of magnitude higher 
than in our study. In our research, the reduction in myogenin coincided with a delay in 
differentiation and a reduction in the total number of multinucleated myotubes, which 
indicates that nanomolar arsenic levels are having a physiological effect on cellular 
differentiation.   
Additionally, our results indicate that Mef2c gene expression and nuclear 
translocation was also reduced an average of 2.6-fold in arsenic exposed cells. Mef2c is a 
transcription factor that is essential for muscle differentiation and is activated by 
myogenin (Dodou and Xu, 2003). The promoter for myogenin contains a Mef2 binding 
site, which provides a way for maintaining myogenin expression in muscle cells 
(Edmondson et al., 1992; Molkentin and Olson, 1996). Thus, the 2 sets of transcription 
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factors work cooperatively to regulate skeletal muscle genes Mef2c deletion in the 
skeletal muscle of mice results in lethality before birth (Lin et al., 1997) and disorganized 
myofibers, which are due to disorganized sarcomeres and the loss of M-line encoding 
proteins such as myomesin (Potthoff et al., 2007a). Like myogenin, Mef2 appears to play 
a role in myotube and myofiber formation. To our knowledge, this is the first time that 
arsenic has been shown to alter Mef2 levels. However, whether the reduction in Mef2c is 
an indirect effect due to the loss of myogenin or whether arsenic can directly alter 
myogenin expression is unclear.  
It has been shown that the methylation status in the myogenin promoter correlates 
with its expression and with muscle differentiation (Lucarelli et al., 2001; Palacios et al., 
2010).  To this end, we examined the DNA methylation patterns in the myogenin 
promoter region. Although there is a weak CpG island in myogenin promoter, there is a 
relatively high density of CpGs from -473 bp to +90 bp,. The results indicate that there 
are two hypermethylated CpGs at -236 and -126 in the arsenic exposed C2C12 cells. 
Interestingly, a hypomethylated CpG at -207 was also detected in the arsenic treatments. 
Since the methylated CpGs may directly interfere gene activation by preventing the 
binding of potential transcription factors or modifications of histone tails, identification 
of potential arsenic mediated transcription factors that could interact with the 
hypomethylated CpG at -207, as well as hypermethylated CpG at -236 and -126, is 
currently under study. Additionally, chromatin immunoprecipitation (ChIP) were also 
performed to investigate the relationship between DNA methylation and histone 
modification at H3K9-Me2/Me3 on the myogenin promoter from -481bp to -28bp. Our 
 49 
results show no correlation between the differentially methylated CpGs and the formation 
of transcriptional repressive heterochromatin in myogenin promoter, indicating that 
H3K9 methylation does not play a major regulatory role in myogenin expression in 
arsenic treatment (data not shown). Moreover, we did examine the expression of DNMT1, 
DNMT3a, and DNMT3b, as well as cellular concentrations of SAM, but there were no 
changes between control and arsenic-exposed cells (data not shown). Recently, 
demethylation of CpGs in the myogenin promoter from -192bp to +58bp has been 
reported in during differentiation of C2C12 cells (Palacios et al., 2010). Our results show 
a hypermethylated CpG (CpG #8, -126bp) in arsenic-exposed C2C12 cells. Moreover, an 
enhancer binding site (-255bp to -241bp) was predicted in the myogenin promoter, which 
is in the same area where we identified a hypermethylated CpG (CpG #3, -236bp).  
Therefore, our findings suggest that these two hypermethylated CpGs may reduce the 
transcriptional activation of myogenin, or block enhancer binding in the myogenin 
promoter during arsenic exposure.     
Collectively, our results indicated that 20nM sodium arsenite results in delayed 
differentiation in C2C12 mouse myocyte cells. The delayed muscle differentiation was 
caused by the reductions in myogenin mRNA expression and reduced nuclear 
localization of myogenin protein. Repressed myogenin expression was likely due to 
abnormal DNA methylation in the myogenin promoter, as well as the reduced expression 
of Mef2c, which is a transcription factor that contributes to myogenin expression. A 
delay in muscle cell differentiation could lead to improper organization of myofibers, 
 50 
which ultimately can have serious physiological consequences on the organism at arsenic 
concentrations that are below the current drinking water standard.   
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Table 2.1 Primers for QPCR and bisulfite sequencing  
                                                                                                                                                                                                      
QPCR 
Primer              Forward (5’ to 3’)            Reverse (5’ to 3’)       Annealing temp (oC) 
Gapdh              tgcgacttcaacagcaactc       atgtaggccatgaggtccac         62.5 
Myogenin      ccaacccaggagatcatttg         acgatggacgtaagggagtg          61 
Ptgis  tgccagcttccttaccaggatgaa   taagagtgtgggtccaggagaaca     61 
Tropomyosin tgaaagtcattgaaagccgagccc  agcaatgtgcttggcctctttcag       56 
Mef2c     aggatcaccggaacgaattccact  gcatgcgcttgactgaaggactt         61 
Socs3      agcagatggagggttctgctttgt    attggctgtgtttggctccttgtg          61   
 
Bisulfite Sequencing 
Primer              Forward (5’ to 3’)              Reverse (5’ to 3’)                           CpG # 
BS-MSP-1      ttttggattatggaggagaga        ccccaccctacaaacctac         #1 to #7 
BS-MSP-2      ggaaggggaattatatgtaattt      aaataattttccccatcataaa        #8 to #11 
BS-MSP: Bisulfite sequencing- methylation specific PCR 
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Fig. 2.1 Arsenic exposure delays C2C12 cell differentiation.  After 3 days of growth, 
myoblast cells grown in growth medium with or without 20nM arsenic (A and B) were 
switched to differentiation medium for 4 days (C and D). Myotube formation is indicated 
by the arrows. Photographs are representative examples from 4 plates/day/group.  
Myotubes that had 3 or more nuclei were counted from 4 random areas per plate (n=4 
plates/day/group) (E) and statistical differences (*) in the percentage of myotubes formed 
was determined by Student’s t-test (p < 0.05). 
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Fig. 2.2 Arsenic alters myogenin nuclear localization and mRNA expression.  Control 
cells on day 0, 2, and 4 of differentiation (A-C) and 20nM arsenic treated cells on day 0, 
2, and 4 of differentiation (D-F) were used to examine myogenin localization by 
immunofluorescence. White arrows indicate nuclei that are expressing myogenin.  
Pictures are representative examples from 4 wells/day/group.  The percentage of nuclei 
expressing myogenin (G) was determined by counting the number of nuclei expressing 
myogenin per total cells in each photo taken (n ≥ 5).  Myogenin RNA expression was 
determined by QPCR (H). Values were normalized against GAPDH as a housekeeping 
gene, with each sample run in triplicate (n=4 plates/day/group).  Statistical differences (*) 
were determined by Student’s t-test (p < 0.05). 
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Fig. 2.3 Changes in the mRNA expression of tropomyosin, Mef2C, Soc3, and Ptgis.  
Tropomyosin (A), Mef2C (B), Socs3 (C), and Ptgis (D) RNA expression was determined 
by QPCR.  The data is expressed in number of molecules/100ng cDNA + standard 
deviation.  Values were normalized against GAPDH as a housekeeping gene, with each 
sample run in triplicate (n=3-5 plates/day/group).  Statistical differences (*) were 
determined by Student’s t-test (p < 0.05).  
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Fig. 2.4 Immunofluorescence of Mef2C.  Mef2C protein expression was examined on 
day 0, 2, and 4 in control (A-C) and 20nM arsenic treated cells (D-F). Pictures are 
representative examples from 4 wells/time point/group. Differences in expression 
between control and treated cells (G) were determined by measuring the intensities of the 
nuclei in each photo taken (n ≥ 5).  Nuclear intensities were normalized to background 
values and statistical differences (*) were determined by Student’s t-test (p < 0.05). 
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Fig. 2.5  Arsenic alters the methylation pattern on the myogenin promoter.   
A portion of the myogenin promoter (-473 to +90) was examined for CpG sites and 
potential transcription factor binding sites by MOTIF Search (http://motif.genome.jp/). 
Bolded nucleotides indicate a CpG site and the number denotes its order.  Underlines 
signify putative transcription factor binding sites, and the transcriptional start site is 
indicated with an arrow (A).  Bisulfite sequencing was performed to determine the 
methylation status at each of the CpG sites in clones from control and 20nM arsenic 
exposed cells.  Open circles denote nonmethylated sites and closed circles denote 
methylated sites (B).  The percentage of methylated Cs was calculated for each CpG site 
(C), and statistical differences (*) were determined using a Chi-Square test (p < 0.05). 
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Abstract 
Arsenic is toxicant commonly found in water systems around the world. Chronic 
arsenic exposure can result in adverse developmental effects such as increased neonatal 
death, stillbirths, and miscarriages, as well as low birth weight and altered locomotor 
activity. Our previous study indicated that 20nM sodium arsenite exposure to C2C12 
mouse myocyte cells resulted in delayed myoblast differentiation, because of reductions 
in myogenin expression, the transcription factor that differentiates myoblasts into 
myotubes.  In this study, several mechanisms by which arsenic could alter myogenin 
expression were examined.  Arsenic exposure to differentiating C2C12 cells resulted in 
altered histone methylation and acetylation status on the myogenin promoter, as 20nM 
arsenic increased H3K9 dimethylation (H3K9me2) and H3K9 trimethylation (H3K9me3) 
by 3-fold near the transcription start site of myogenin, which is indicative of increased 
heterochromatin formation, and arsenic exposure reduced H3K9 acetylation (H3K9Ac) 
by 0.5-fold, which is indicative of reduced euchromatin formation. In addition to the 
altered histone remodeling status on the myogenin promoter, protein and mRNA levels of 
Igf-1, a myogenic growth factor, were significantly repressed by arsenic exposure. 
Moreover, a 2-fold induction of Ezh2 expression, as well as an increased recruitment of 
Ezh2 (3.3-fold) and Dnmt3a (~2-fold) to the myogenin promoter at the transcription start 
site (-40 to +42), were detected in the arsenic-treated cells. Together, we conclude that 
the repressed myogenin expression in arsenic-exposed C2C12 cells was likely due to a 
combination of the reduced expression of Igf-1, the enhanced nuclear expression and 
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promoter recruitment of Ezh2, and the altered histone remodeling status on myogenin 
promoter (-40 to +42). 
 
Keywords:  Arsenite; myocyte; Myogenin; Histone remodeling; Igf-1; Ezh2 
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Introduction 
  Arsenic is a toxicant commonly found in water systems around the world. 
Chronic arsenic poisoning is a global health problem affecting millions of people (Cherry 
2008; McDonald 2007; Medrano et al. 2010; Wang et al. 2009) which can result in 
cancer, central nervous system and sensory deficits, effects on development, and 
neuromuscular deficits (Andrew et al. 2007; Benbrahim-Tallaa and Waalkes 2007; Kozul 
et al. 2009; Mohammad et al. 2009). Unfortunately, the mechanisms responsible these 
multiple adverse outcomes remain largely unclear and likely are multi-factorial. 
Arsenic is also a developmental toxicant. In humans and rodents, arsenic can 
traverse the placenta and this exposure results in adverse developmental effects, such as 
increased neonatal death and stillbirths (Agusa et al. 2010; Concha et al. 1998; 
Markowski et al. 2011; Raqib et al. 2009; von Ehrenstein et al. 2006).  In fish, arsenite-
exposed zebrafish embryos have reduced survival and delayed hatching, malformations 
in the spinal cord and heart, and disordered motor axon projections (Li et al. 2009). 
Recently, negative effects of arsenic on early embryonic development have been reported 
(Flora and Mehta 2009; Stummann et al. 2008). Results from mouse embryonic stem 
cells indicate that 10 mM arsenic inhibits cardiac differentiation by reducing the 
formation of embryoid bodies, which is an essential step for stem cell differentiation 
(Stummann et al. 2008). Arsenic (1ppb) treated human stem cells show altered 
pluripotency and significant down regulation of genes indicative of all the three germ 
layers (Flora and Mehta 2009). 
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Arsenic-mediated adverse effects on muscle differentiation have also been 
reported. In killifish (Fundulus heteroclitus), arsenic exposed parents had offspring with 
increased trunk curvatures, which was correlated with changes in myosin light chain, type 
II keratin, tropomyosin, and parvalbumin expression in the hatchlings (Gonzalez et al. 
2006). Arsenic exposure to mouse C2C12 myoblasts delayed their differentiation into 
myotubes, likely due to a reduction in the expression of myogenin (Steffens et al. 2011). 
In rodent models, arsenic suppresses the regeneration of injured muscles (Yen et al. 
2010), alters pulmonary structure and function in utero by increasing the smooth muscle 
actin in the lung (Lantz et al. 2009), and disrupts the smooth muscle integrity around the 
blood vessels in the heart (Hays et al. 2008). Collectively, these results suggest that 
arsenic acts as a developmental toxicant by affecting the development of the musculature. 
The development of skeletal muscle is regulated by several myogenic 
transcription factors, such as Myo D, myogenin, and myocyte enhancer factor 2 (Mef2). 
In muscle differentiation, MyoD and Mef2 are early markers, which are expressed during 
myoblast determination, and they then regulate myogenin, which induces terminal 
differentiation by converting myoblasts into myotubes (Carvajal and Rigby 2010; 
Gianakopoulos et al. 2011; Yokoyama and Asahara 2011). Moreover, other signaling 
molecules, such as insulin-like growth factor 1 (Igf-1) and myostatin, regulate myogenin 
expression via the PI3K/AKT pathway during skeletal muscle differentiation (Alzhanov 
et al. 2010; Artaza et al. 2002; Yang et al. 2007). In addition, chromatin-modifying 
enzymes also regulate muscle development by epigenetically repressing myogenic 
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transcription factors (Albert and Peters 2009; McDonald and Owens 2007; Ohkawa et al. 
2007). 
Recently, arsenic-induced alterations in DNA methylation and histone 
modifications have been suggested to play a role in carcinogenesis and the fetal origins of 
diseases (Arita and Costa 2009; Baccarelli and Bpllati 2009; Ren et al. 2010). Altered 
DNA methylation may occur since the pathway for biotransformation of arsenic also 
relies on methylation (Baccarelli and Bpllati 2009; Ren et al. 2010; Vahter 2009). To this 
end, studies have shown that arsenic exposure results in both hypermethylation and 
hypomethylation at global and gene specific levels, thereby leading to aberrant gene 
expression. For example, mice exposed to arsenic have reduced p16 expression in lung 
tumors due to hypermethylation of the p16 gene. In humans, arsenic induces DNA 
hypermethylation in the promoters of the p53 and p16 genes (Benbrahim-Tallaa and 
Waalkes 2007; Chanda 2006; Salnikow and Zhitkovich 2008; Zhou et al. 2008). 
Moreover, a significant relationship between arsenic exposure and promoter 
hypermethylation of two tumor suppressor genes, PRSS3 and RASSF1A, was identified 
in a population-based study of human bladder cancer (Marsit et al. 2006). In addition to 
DNA methylation, arsenic also has a role in histone modification. H3K9 dimethylation 
(H3K9me2) and H3K9 trimethylation (H3K9me3), both markers of gene silencing, were 
induced at the global level in human lung carcinoma A549 cells and in normal human 
bronchial epithelial BEAS-2B cells upon exposure to 2.5μM arsenic (Zhou et al. 2008).  
Acetylation of K9 in histone H3 (H3K9 Ac), which represents transcriptional activation, 
was reduced by 50% at a global level in human UROtsa cells upon exposed to arsenic 
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(3μM) for 7 days (Chu et al. 2011). Moreover, arsenic represses steroid hormone-
mediated transcription by disrupting acetylation of K18 in histone H3 (H3K18) at the 
estrogen-responsive pS2 promoter (Barr et al. 2009). Collectively, these and other reports 
suggest that arsenic can epigenetically alter gene expression via either DNA methylation 
or histone modifications.  
  Our previous studies indicate that 20nM sodium arsenite delays the 
differentiation of C2C12 mouse myoblast cells by repressing myogenin expression, 
which was likely due to the altered DNA methylation patterns on myogenin promoter and 
the decreased nuclear translocation of Mef2 (Steffens et al. 2011). Since the potential 
regulatory mechanisms responsible for the arsenic-induced delay in muscle 
differentiation remain largely unclear, the objectives of the present study were to examine 
whether the arsenic-induced abnormal methylation patterns would lead to changes in 
chromatin structures on myogenin promoter and investigate whether other muscle 
transcription and growth factors were altered by arsenic exposure.  
Methods 
Cell culture.  
C2C12 myoblasts were maintained in growth medium (GM) consisting of 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 1% L-
glutamine and 1% penicillin/streptomycin solution. Differentiation medium (DM) was 
DMEM containing 2% horse serum, 1% L-glutamine and 1% penicillin/streptomycin 
solution (Kubo 1991). For differentiation studies, 15x10
4
 cells were seeded in a 150mm 
dish with or without 20nM arsenic as sodium arsenite, and then cultured for in growth 
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medium for 3 days (GM3). On day 4, the culture medium was changed to differentiation 
medium (DM) with or without 20nM arsenic to induce myotube differentiation. Cells 
were cultured for 2 days (DM2) and then harvested. 
Igf-1 mRNA Expression.  
C2C12 cells were cultured with or without 20nM arsenic as sodium arsenite as 
described above, harvested at differentiation hour 12, 24, 36, and 48 (n=3 per group per 
time point), and total RNA extracted. The mRNA expression of Igf-1 was quantified 
using RT
2
 SYBR Green Supermix (Qiagen) according to manufacturer’s instructions. 
The oligonucleotides used for qPCR were Igf-1 Forward: 5’-GAC CGA GGG GCT TTT 
ACT TCA-3’, Reverse: 5’-GGA CGG GGA CTT CTG AGT CTT-3’; and Gapdh 
Forward: 5’-TGC GAC TTC AAC AGC AAC TC-3’, Reverse: 5’-ATG TAG GCC ATG 
AGG TCC AC-3’. Samples were run in triplicate, and relative gene expression was 
calculated using the comparative threshold (Ct) method (Livak and Schmittgen 2001).  
Chromatin Immunoprecipitation (ChIP).  
C2C12 cells were cultured with or without 20nM sodium arsenite as described 
above and harvested on differentiation day 2 (DM2) (n=4 per group per day). Chromatin 
preparation and immunoprecipitation was performed according to standard protocols 
(Abcam Inc., Cambridge, MA). The antibodies used for ChIP assays were: anti-Ezh2 
(Millipore Inc., Temecula, CA), anti-Mef2 (Santa Cruz Biotech Inc., Santa Cruz, CA), 
anti-Dnmt3a and –Dnmt3b (Imgenex Inc., San Diego, CA), and anti-H3K9 Ac, -H3K9 
Me2, and -H3K9 Me3 (Abcam). Normal rabbit and mouse IgG (Santa Cruz) were used as 
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negative controls. Quantification of precipitated DNA was performed by qPCR using 
SYBR green and myogenin promoter-specific primers. The oligonucleotides used for 
ChIP assays were ChIP 1 Forward: 5’-TAA TCA AAT TAC AGC CGA CGG CCT CC-
3’, Reverse: 5’-GCT GCA CAT CAA GAC GTT TCC AGT-3’; ChIP 2 Forward: 5’-
CGT CTT GAT GTG CAG CAA CAG CTT-3’, Reverse: 5’-CAT TTA AAC CCT CCC 
TGC TGG CAT-3’; and ChIP 3 Forward: 5’-GGG TTT AAA TGG CAC CCA GCA 
GTT-3’, Reverse: 5’-TCA TAC AGC TCC ATC AGG TCG GAA-3’ (see Fig. 2 for 
specific locations of each ChIP assay). Relative enrichment of the myogenin promoter 
DNA relative to a no-antibody control was calculated based on difference in threshold 
(Ct) values (2[Ctantibody−CtIgG])(Nelson et al. 2006). 
Immunofluorescence analysis of Ezh2, MyoD, and Igf-1.  
C2C12 cells were seeded in Lab-tek II 8-well chamber slides (Nunc) at a 
concentration of 100 cells/well.  To determine the expression Ezh2 and MyoD, cells were 
cultured with or without 20nM sodium arsenite as described above and examined for 
specific protein expression on differentiation days 0 (GM3) and 2 (DM2) (n=4 wells per 
protein per group per day). For Igf-1 expression, cells were examined on differentiation 
day 0 (GM3) and differentiation hour 24, 36, and 48 (DM2). Cells were fixed with either 
4% paraformaldehyde at room temperature for 20 minutes or methanol at -20 ° C for 5 
minutes, blocked in 1% bovine serum albumin, 0.1% Triton-X100 in PBS, and incubated 
with the appropriate primary antibody for 1 hour at a 1:100 dilution. The secondary 
antibody (1g/mL) conjugated to Alexa Flour 488 (Invitrogen, Carlsbad, CA) was 
incubated with the cells, which were counterstained with DAPI (Invitrogen). Cells were 
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examined by conventional immunofluorescence on a Ti Eclipse Inverted Microscope 
(Nikon, Melville, NY). Ezh2 and MyoD expression was quantified by determining the 
intensities of nuclear staining in six randomly selected fields per well, for a total of four 
independent wells/time point/group. Intensities were expressed as fold-change relative to 
control groups.  For Igf-1 quantification, the number of nuclei expressing Igf-1 was 
counted from six randomly selected fields per chamber, for a total of four independent 
wells/time point/group. 
Statistical analysis.  
Student’s t-test was used for all statistical analysis and p-values of <0.05 were 
considered to be statistically different.  
Results 
Arsenic exposure reduces Igf-1 expression in C2C12 cells. 
  Igf-1 is a potent inducer of muscle differentiation (Musaro et al. 1999). Although 
the Igf-1 responsive elements in the myogenin promoter remain unclear during muscle 
differentiation, it has been shown that Igf-1 induces myogenin expression by targeting 
Mef2 and MyoD to the myogenin promoter in C2C12 cells through the Igf-1/PI3K/AKT 
pathway (Xu and Wu 2000). To this end, we examined whether arsenic exposure would 
alter the expression of Igf-1 in C2C12 cells. Immunofluorescence staining showed no 
significant alternation of Igf-1 expression in myoblasts (GM3) with or without arsenic 
exposure (Fig. 1A).  A time course study was conducted to examine Igf1 expression at 
DM1 (24 hours), DM1.5 (36 hours), and DM2 (48 hours). Interestingly, increased Igf-1 
protein in the nuclei was observed in differentiating myoblasts, compared with 
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undifferentiated myoblasts (see the arrows in Fig. 1A) at DM1 and DM1.5, and by DM2, 
a significant reduction in cellular Igf-1 was observed from cells differentiated in 20nM 
arsenic (Fig. 1A).  An 11.8-fold and 5-fold reduction in the number of nuclei expressing 
Igf-1 was observed in the arsenic-exposed C2C12 cells at DM1 and DM1.5 (Figure 1B).  
qPCR corroborated the immunofluorescence, showing a significant reduction in Igf-1 
mRNA expression by 2.3-fold, 1.8-fold, and 2.1-fold in the arsenic-treated cells at 
differentiation hour 24, 36, and 48, respectively (Fig. 1C). 
Arsenic exposure alters histone remodeling status on the myogenin promoter near the 
transcription start site in C2C12 cells. 
  Our previous study indicated that 20nM sodium arsenite exposure to C2C12 
mouse myocyte cells resulted in delayed differentiation because of a reduction in 
myogenin expression. We hypothesized that the repressed myogenin expression was due 
to abnormal DNA methylation patterns on the myogenin promoter (Steffens et al. 2011).  
Since DNA methylation patterns may affect gene expression by causing histone 
remodeling (Bird 2002) or altering transcription factor availability (Palacios et al. 2010), 
ChIP assays were performed to examine histone remodeling status on the myogenin 
promoter after arsenic exposure to C2C12 cells. Markers of heterochromain (H3K9 Me2 
and H3K9 Me3) and euchromatin (H3K9 Ac) were examined by looking at three 
different areas on the myogenin promoter. ChIP 1 encompasses -114 to –251 of the 
myogenin gene, and arsenic exposure hyper-and hypo-methylates CpG#2 at -236 and 
CpG#5 at -207, respectively. ChIP 2 encompasses -31 to -128, which contains a 
hypermethylated CpG#6 at -126 and Mef2 binding site. ChIP 3 encompassess -40 to +42, 
 75 
and contains an E-box at -13 to -18 and the transcription start site (Fig. 2A). Results from 
ChIP 1 and ChIP 2 showed no significant differences between control and arsenic groups 
with the three histone markers (Fig. 2B). However, chromatin precipitated from ChIP 3 (-
40 to +42 of the myogenin promoter) indicated that H3K9 Me2 and –M3 were 
significantly induced by 3-fold (Fig. 2B), which is indicative of increased 
heterochromatin formation, while H3K9 Ac was reduced by 0.5-fold (Fig. 2B), which is 
indicative of reduced euchromatin formation in arsenic exposed differentiating C2C12 
cells. 
Arsenic exposure increases Ezh2 nuclear expression and recruits Ezh2 to the 
myogenin promoter at the transcription start site. 
  The polycomb Ezh2 methyltransferase (Ezh2) has been reported to play a role in 
the repression of terminal muscle differentiation by epigenetic mechanisms (Caretti et al. 
2004; Juan et al. 2009). Because histone marks were changed by arsenic exposure on the 
myogenin promoter at the TSS, we asked whether arsenic exposure would increase Ezh2 
expression during muscle differentiation. Immunofluorescence staining indicates that the 
nuclear localization of Ezh2 was significantly increased by ~2-fold in cells treated with 
20 nM arsenic (Figs. 3A and 3B). Additionally, results from ChIP assays also showed a 
significant 3.3-fold recruitment of Ezh2 to the myogenin promoter surrounding the 
transcription start site in the arsenic-exposed cells (Fig. 3C). These data indicate that 
Ezh2-mediated gene silencing is increased after arsenic exposure. 
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Arsenic exposure recruits Dnmt 3a, but not Dnmt 3b, to the myogenin promoter  
  Since Ezh2 can silence gene expression by directly recruiting DNA 
methyltransferases (Dnmts) to the target gene’s promoter (Viré et al. 2006), we examined 
the recruitment of Dnmt 3a and Dnmt 3b, which are both de novo DNA 
methyltransferases (Ling et al. 2004), to the myogenin promoter in cells exposed to 20 
nM arsenic. Interestingly, the area surrounding the TSS (ChIP 3) showed a significant 
1.9-fold enrichment in Dnmt3a in arsenic exposed cells (Fig. 4A). However, there was no 
significant difference in the recruitment of Dnmt 3b to the myogenin promoter between 
control and arsenic treatments (Fig. 4B).  
Arsenic exposure reduces the recruitment of Mef2 to the myogenin promoter 
  MyoD and Mef2 are two transcription factors that activate myogenin expression 
by recruiting CBP/p300 co-activator proteins to the myogenin promoter.  These co-
activators possess histone acetyltransferase (HAT) activity, which results in the 
relaxation of chromatin structures (Lu et al. 2000; Ohkawa et al. 2006). Our previous 
study showed a significant reduction in Mef2 nuclear translocation in arsenic-treated 
C2C12 cells during differentiation (Steffens et al. 2011) and we wanted to determine 
whether this reduced nuclear translocation was due to reduced recruitment of Mef2 to the 
myogenin promoter. There is one Mef2 response element in this region (Fig. 2A), so only 
the primers specific for –31 to –128 (ChIP 2) were used. Mef2 recruitment was indeed 
reduced by ~70% on the myogenin promoter after arsenic exposure at DM2 (Fig. 5A). 
The nuclear expression of MyoD was also quantified by immunofluorescence, but there 
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was no change in its expression during the differentiation of arsenic-exposed C2C12 cells 
(Figs. 5B and 5C).     
Discussion 
  Results from the present study, using chromatin immunoprecipitation and 
immunofluorescence staining, illustrate that repressed myogenin expression in arsenic-
exposed C2C12 cells is likely due to a combination of reduced Igf-1 expression, 
enhanced nuclear expression and promoter recruitment of Ezh2, and the altered histone 
remodeling status on the myogenin promoter (-40 to +42). To our knowledge, this may be 
the first report that illustrates the effects of nanomolar arsenic concentration on the 
expression of Ezh2 and Igf-1 on skeletal muscle development. Additionally, this may also 
be the first study that has examined the effects of nanomolar arsenic concentration on the 
histone remodeling status at a gene-specific promoter, since previous, studies have 
examined the effects of arsenic on global histone modifications (Chu et al. 2011; Ramirez 
et al. 2008; Zhou et al. 2009).   
Reduced Igf-1 expression and its role in myogenin expression.  
Igf-1 is considered to be a myogenic growth factor (Chakravarthy et al. 2000).  
Results from control C2C12 cells indicate that nuclear Igf-1 expression was increased in 
a time-dependent manner at DM1 and DM1.5. Two days after the induction of muscle 
differentiation, the levels of Igf-1 were maximal and the protein was diffusely expressed 
within the myotubes. However, in arsenic-exposed C2C12 cells, Igf-1 protein and mRNA 
expression were significantly reduced. Additionally, the expression of myostatin, which 
represses muscle differentiation by antagonizing the Igf-1/PI3K/Akt pathway (Yang et al. 
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2007), was modestly increased in the nuclear fraction of the arsenic-exposed C2C12 cells 
(data not shown). Therefore, the increased nuclear Igf-1 expression may play a role in 
initiating skeletal muscle differentiation. Indeed, the translocation of Igf-1 into the nuclei 
has been reported in regenerating human muscle satellite cells, in which Igf-1 protein was 
detected in the nuclei at 24 hours after the start of regeneration, and then was diffusely 
expressed in the myofibres after 72 hours, while myogenin mRNA were significantly 
increased by 2-fold at 24h and ~3-fold after 72 hours (McKay et al. 2008).  In contrast, 
mice lacking Igf-1 have reductions in the number of formed muscle fibers and myogenin 
expression is significantly lowered (Miyake et al. 2007). 
Although the molecular mechanisms about how Igf-1 transcriptionally induces 
myogenin mRNA are not fully understood, it has been suggested that IGF1/PI3K/AKT 
target multiple nuclear factors that bind Mef2 and MyoD to PI3K/Akt-responsive 
elements residing within the 133-bp proximal myogenin promoter (Xu and Wu 2000). 
Moreover, inhibition of Igf-1 expression in C2C12 cells represses myogenin expression 
due to recruitment of the polycomb protein Ezh2 and the formation of hypoacetylated and 
hypermethylated histones on the myogenin promoter between -106 to +91, all of which 
act to form closed chromatin structures (Serra et al. 2007). In our arsenic-exposed C2C12 
cells, we observed the reduction of Igf-1 expression, as well as repressed Mef2 
recruitment on the myogenin promoter.  Additionally, Ezh2 enrichment, increases in 
histone marks indicative of heterochromatin and a reduction in histone marks indicative 
of euchromatin were detected on the myogenin promoter at -40 to +42 following arsenic 
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exposure. Therefore, our results indicate that nanomolar concentrations of arsenic repress 
myogenin expression through Igf-1-mediated regulatory mechanisms.   
Arsenic exposure modifies histones near the TSS in the myogenin promoter.  
The expression of muscle genes during myoblast differentiation is regulated by 
chromatin structure, in which heterochomatin is present at muscle-regulatory elements in 
undifferentiated myoblasts and then as the myoblasts enter the differentiation process, the 
chromatin structure becomes permissive (Guasconi and Puri 2009; Saccone and Puri 
2010). Our ChIP assays indicate that arsenic-exposed C2C12 cells have a 3-fold increase 
of repressive chromatins (H3K9 Me2 and H3K9 Me3), and a 50 % reduction of 
permissive chromatins (H3K9 Ac) at the TSS (-40 to + 42) of the myogenin promoter 
when they should be undergoing differentiation. This area of increased heterochomatin is 
at the 133-bp proximal myogenin promoter region, and encompasses a TATA box, a 
MyoD site (E-box), and the transcription start site (Buchberger et al. 1994; Yee and 
Rigby 1993). The proximal myogenin promoter has been identified as a critical 
regulatory element for myogenin expression (Buchberger et al. 1994; Deato and Tjian 
2007; Yee and Rigby 1993). For example, it has been demonstrated that the binding of 
TRF3/TAF3 (TBP-related factor 3/TATA-binding protein-associated factors 3) to the 
TATA box and recruitment of RNA Pol II-ser5 to the proximal promoter are both required 
to activate the myogenin promoter in differentiating C2C12 cells (Deato and Tjian 2007). 
Therefore, the altered chromatin conformation by arsenic exposure may affect the 
accessibility of basal transcription factors to the proximal promoter and thereby result in 
the reduction of myogenin in differentiating C2C12 cells exposed to arsenic.  
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To date, several metals have been reported to repress the basal machinery via histone 
remodeling on promoter regions of some genes. For instance, in mouse Hepa-1 cells, 
chromium blocks the transcription of the Cyp1a1 gene by inhibiting RNA polymerase II 
recruitment to the proximal promoter through the reduced acetylation of H3K9 
(Schnekenburger et al. 2007). In human lung carcinoma A549 cells and normal bronchial 
epithelial BEAS-2B cells, chromate silences the expression of the tumor suppressor gene 
MLH1 via induction of H3K9 methylation in its promoter (Sun et al. 2009). Moreover, 
nickel silences the gpt (bacterial xanthine guanine phosphoribosyltransferase) transgene 
in G12 Chinese hamster cells due to increased H3K9 Me2 enrichment (Chen et al. 2006). 
Therefore, these and other results suggest that arsenic-mediated histone modifications at 
the myogenin proximal promoter may play a potential regulatory role in reducing 
myogenin expression.  
Induced EZH2 expression and its potential role in repressing myogenin expression 
  A previous report indicated that increased Ezh2 expression correlates to reduced 
myogenin expression, and silenced Ezh2 expression induces myogenin expression in 
differentiating C2C12 cells (Juan et al. 2009). Consistently, in our arsenic-exposed 
C2C12 cells, which have been shown to exhibit delayed muscle differentiation due to 
reductions in myogenin expression (Steffens et al. 2011), the nuclear expression of Ezh2 
was significantly enhanced by 2-fold.  Therefore, Ezh2 seems to be one of the potential 
mechanisms involved in abnormal muscle development due to arsenic. Indeed, Ezh2 has 
been reported as a negative muscle regulator.  For example, in dystrophic muscles, 
muscle regeneration is inhibited by recruitment of Ezh2 and Dnmt3b in muscle satellite 
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cells, which thereby represses Notch-1 expression (Acharyya et al. 2010). Interestingly, 
results from our ChIPs also demonstrate a significant increased recruitment of Ezh2 (3.3-
fold) and Dnmt3a (~2-fold) to the myogenin promoter at the TSS in arsenic–treated cells. 
Recruitment of Dnmt3a to the myogenin promoter at the TSS may be a reason why 55% 
of the CpGs at +3 on the myogenin promoter were methylated in arsenic treatments 
(Steffens et al. 2011). Such a high methylation rate of CpG at +3 may alter myogenin 
expression. For example, a recent study has shown that CIBZ, a methyl-CpG-binding 
protein, suppresses muscle development by directly binding to the myogenin proximal 
promoter and thus inhibiting myogenin expression (Oikawa et al. 2011). Luo and 
coworkers have demonstrated, using C2C12 cells, that methyl-CpG-binding protein 2 
(MCB2) suppresses muscle terminal differentiation by inducing heterochromatin 
formation (H3K9 Me2) at the myogenin proximal promoter (Luo et al. 2009). Therefore, 
these results suggest that the enriched Dnmt3a after arsenic exposure may highly 
methylate CpG site at +3, thereby recruiting the methyl-CpG-binding proteins, which 
results in the silencing of the myogenin gene by increasing heterochromatin formation 
surrounding the TSS of myogenin.  
Since Ezh2 has been reported to silence myosin heavy chain (MHC) and muscle 
creatine kinase (MCK) by enzymatic methylation of H3K27 (Caretti et al. 2004), we also 
examined the tri-methylation of histone H3K27 on myogenin promoter at TSS. However, 
there was only a 1.6-fold induction of H3K27 Me3 at TSS in arsenic treatments (data not 
shown). Therefore, it appears that the induced Ezh2 expression may repress myogenin 
expression through recruiting Dnmt3a, rather than performing histone H3K27 
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trimethylation, on myogenin promoter at TSS in arsenic treatments.  To date, the 
regulatory mechanisms about how arsenic exposure induces Ezh2 expression remain 
largely unclear. Thus, further examinations of arsenic-mediated Ezh2 expression are 
required in the future.  
During muscle differentiation, the methylation status of the myogenin promoter 
correlates with myogenin expression (Lucarelli 2000; Palacios et al. 2010). After arsenic 
treatment of C2C12 cells, two hypermethylated CpGs at -236 and -126 and a 
hypomethylated CpG at -207 were detected (Steffens et al. 2011). Recently, two muscle 
transcription factors, SP1 (trans-acting transcription factor 1) and Snail (Snail homolog 1, 
Drosophila), have been predicted to play a role in myogenin expression by binding to 
myogenin promoter at sites -234 to -222 for SP1 and -207 to -201, for Snai1 (Fuso et al. 
2010). We did performed DNA-protein pull down and ChIP assays in differentiating 
C2C12 cells treated with or without 20nM arsenic, but, no differences in DNA-protein 
binding of SP1 and Snail on the myogenin promoter was detected between control and 
arsenic groups (data not shown). Therefore, the reasons for and the consequence of these 
arsenic-induced abnormal CpGs in the myogenin promoter remain unclear. 
In conclusion, our results indicate that 20 nM sodium arsenite reduces Igf-1 
expression in differentiating C2C12 cells. Such decreased Igf-1 may be responsible for 
the reduced recruitment of Mef2 on the myogenin promoter, thereby decreasing 
myogenin expression after arsenic exposure. Additionally, arsenic exposure to C2C12 
mouse myocyte cells alters histone remodeling status on the myogenin promoter 
surrounding the transcription start site, which may reduce the accessibility of basal 
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transcription factors and repress myogenin expression. Moreover, the nuclear expression 
of Ezh2, which is known as a negative muscle regulator, was enhanced by arsenic 
exposure in C2C12 cells. Collectively, we conclude that, rather than acting alone, these 
altered regulatory mechanisms by arsenic exposure seem to be connected and co-
contribute to the repressed myogenin gene in C2C12 cells. 
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Fig. 3.1 Arsenic exposure reduces Igf-1 expression and nuclear translocation in 
C2C12 cells. C2C12 cells were cultured with or without 20nM sodium arsenite in growth 
medium for 3 days (GM3) and then differentiation medium (DM) for 1, 1.5, or 2 days to 
    Control     20 nM arsenic 
20 µm 
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DM2 
DM1 
DM1.5 
Igf-1 DAPI Merge Igf-1 DAPI Merge 
B. C. 
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examine Igf1 expression by immunofluorescence. Arrows indicates nuclei expressing Igf-
1 (A). The percentage of nuclei expressing Igf-1 was determined by randomly selecting 6 
fields per chamber, for a total of four chambers/time point/group. Results were averaged 
and statistical differences (*) determined by Student’s t-test (p<0.05) (B). Igf-1 mRNA 
expression from C2C12 cells in the presence and absence of 20 nM arsenic in 
differentiation medium for 12 hours, 24 hours, 36 hours, and 48 hours was quantified by 
qPCR. Each sample was run in triplicate (n=3 plates/day/group) and results were 
normalized to GAPDH and expressed as normalized fold-change to relative to C2C12 
12hr control) cells. Statistical differences (*) were determined by Student’s t-test 
(p<0.05) (C). 
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Fig. 3.2 Arsenic exposure alters the histone remodeling status of the myogenin 
promoter in C2C12 cells.  Schematic diagram of the myogenin promoter, showing the 
transcription start site (TSS), Mef2 response element, TATA box, E-box (MyoD binding 
MEF2 E-Box 
(MyoD) 
ChIP 3 
ChIP 2 ChIP 1 
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site), CpG sites, and the locations where the three ChIP assays were performed. Black 
triangles represent two hypermethylated CpGs at -236 and -126, whereas the white 
triangle represents a hypomethylated CpG at -207 on myogenin promoter after sodium 
arsenite exposure to differentiating C2C12 cells (Steffans et al. 2011) (A). ChIP assays 
were performed with antibodies against di-methylated H3K9 (H3K9 Me2), tri-methylated 
H3K9 (H3K9 Me3), and acetylated H3K9 (H3K9 Ac) using DNA harvested from DM2 
C2C12 cells exposed to 0 or 20nM sodium arsenite. Enriched DNA fragments from these 
ChIP assays were analyzed by qPCR and expressed as relative fold enrichment. Each 
sample was ran in triplicate (n=4 plates/day/group) and statistical differences (*) were 
determined by Student’s t-test (p<0.05) (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
                   
        Ezh2            DAPI           Merge             Ezh2             DAPI                 Merge 
           
           
           
 
 
        
 
  Fig. 3.3 Arsenic exposure enhances Ezh2 nuclear expression and recruits Ezh2 to 
the myogenin promoter near the transcription start site.  Ezh2 protein expression was 
examined by immunofluorescence in C2C12 cells exposed with or without 20nM arsenic 
in the growth medium for 3 days (GM3) and in the differentiation medium for 2 days 
(DM2). Pictures are representative examples from 4 independent wells/time point/group 
20 µm 
GM3 
DM2 
Control 20nM Arsenic A. 
B. 
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(A). Differences in Ezh2 protein expression between control and arsenic-treated cells 
were determined by measuring the nuclear intensiy in 6 randomly selected fields per 
chamber, for a total of four independent experiments/time point/group. Intensities are 
expressed as relative nuclear expression (B). ChIP was performed with antibodies against 
Ezh2 using C2C12 cells at DM2. Immunoprecipitated DNA was analyzed by qPCR and 
the data is expressed as relative fold enrichment (C). Each sample was run in triplicate 
(n=4 plates/day/group) and statistical differences (*) were determined by Student’s t-test 
(p<0.05).   
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Fig. 3.4 Ezh2 recruits Dnmt 3a, but not Dnmt 3b, to the myogenin promoter.  ChIP 
was performed at the TSS (-40 to +42) of the myogenin promoter using antibodies 
against Dnmt 3a (A) and Dnmt 3b (B) with DNA from C2C12 cells at DM2 exposed to 0 
or 20nM arsenic. Enrichment of Dnmts was examined by qPCR and data are expressed as 
relative fold enrichment. Each sample was run in triplicate (n=7 plates/day/group) and 
statistical differences (*) were determined by Student’s t-test (p<0.05). 
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Fig. 3.5 Arsenic exposure reduces the recruitment of Mef2 to the myogenin 
promoter but does not alter MyoD expression.  On DM2 in cells cultured with or 
without 20nM arsenic, ChIP was performed at the ChIP 2 region with antibodies against 
20 µm 
A. 
B. 
GM3 
DM2 
Control 20nM Arsenic 
C. 
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Mef2. Enriched DNA fragments were analyzed by qPCR and are expressed as relative 
fold enrichment (A). MyoD expression in C2C12 cells exposed with or without 20nM 
arsenic at GM3 and DM2 was examined by immunofluorescence (B). MyoD protein 
expression was quantified by measuring nuclear intensities in 6 randomly selected fields 
per chamber, for a total of four chambers/time point/group. Intensities were expressed as 
relative nuclear expression (C). Each sample was ran in triplicate (n=4 plates/day/group) 
and statistical differences (*) were determined by Student’s t-test (p<0.05). 
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Abstract 
 
Epidemiological studies have correlated arsenic exposure with adverse 
developmental outcomes such as stillbirths, neonatal mortality, and low birth weight.  
Additionally, arsenic-induced effects on neuronal formation and function, such as 
reduced intellectual function and reductions in neuronal cell migration and maturation, 
and changes in skeletal muscle cell formation, alteration of muscle fiber subtype, and 
changes in locomotor activity, have been reported. The current study used P19 mouse 
stem cells to examine whether arsenic exposure could alter their differentiation into 
skeletal muscle and neurons. When P19 cells were exposed to 0.5M sodium arsenite, 
their differentiation into embryoid bodies was not altered. However, arsenic suppressed 
their differentiation into muscles and neurons, as evidenced by morphological changes 
accompanied by a significant reduction in myosin heavy chain and Tuj1 expression. Real 
time PCR, immunofluorescence, and immunoblotting were used to confirm that the 
altered differentiation was due to the repression of the muscle-and neuron-specific 
transcription factors such as Pax3, Myf5, MyoD, myogenin, neurogenin 1, neurogenin 2, 
and NeuroD in the arsenic-exposed cells.  The reductions in transcription factors 
expression appear to be caused by repressed Wnt/β-catenin signaling pathways in early 
embryogenesis, as evidenced by decreased β-catenin expression in the arsenic-exposed 
embryoid bodies on differentiation days 2 and 5. This study demonstrates that arsenic can 
disturb the embryonic differentiation process by repressing the Wnt/β-catenin signaling 
pathway. More importantly, this study may provide insight into how arsenic exposure 
affects skeletal and neuronal differentiation during embryogenesis.   
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Introduction 
Exposure to arsenic in drinking water is a global health issue affecting millions of 
people (Cherry et al., 2008; Medrano et al., 2010; Mohammad et al., 2009) and it has 
been associated with a variety of adverse effects including cancer, skin lesions, and 
cardiovascular disease (Benbrahim-Tallaa & Waalkes, 2007; Schuhmacher-Wolz et al., 
2009; States et al., 2009). Arsenic can also act as a developmental toxicant. In humans 
and mice, arsenic can pass through the placental barrier (Concha et al., 1998; Jin et al., 
2006; Xie et al., 2007) and, in utero exposure of arsenic via the mother’s drinking water 
can result in increases in neonatal death and miscarriages, and reduced birth weight 
(Agusa et al., 2010; Concha, et al., 1998; Markowski et al., 2011; Raqib et al., 2009; von 
Ehrenstein et al., 2006).    
Additionally, arsenic can cross the blood-brain barrier (BBB) and accumulate in 
the brain (Au et al., 2008; Jin, et al., 2006; Kiguchi et al., 2010; Knipp et al., 2007; Xi et 
al., 2010), which may provide a rationale for the correlations between embryobnic 
arsenic exposure and  neurological diseases, such as mental retardation, hearing 
impairment, and lower intelligence quotient scores (Bencko et al., 1977; Calderon et al., 
2001; Dakeishi et al., 2006; Tsai et al., 2003). Arsenic exposure can.inhibit neurite 
outgrowth in Neuro-2a (N2a) cells by blocking the activation of adenosine 
monophosphate-activated kinase (AMPK) pathway (Wang et al., 2010). In primary 
embryonic rat neuroepithelial cells, arsenic inhibits cell cycle progression in all cell cycle 
phases, and the arrested cell cycle phases were associated with the induced apoptosis 
(Sidhu et al., 2006). Piao and coworkers have observed that arsenic exposure via drinking 
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water induces degeneration of neuronal cells in the cerebrum and cerebellum of mice 
(Piao et al., 2005). Moreover, in rats, oral arsenic administration resulted in thinly 
myelinated axons in peripheral sensory nerves, caused by the induction of reactive 
oxygen species (Garcia-Chavez et al., 2007).  
Arsenic-mediated adverse effects on muscle differentiation have also been 
reported. For example, arsenic exposure to mouse C2C12 myoblasts resulted in delayed 
muscle differentiation into myotubes, due to a reduction in the expression of myogenin 
(Steffens et al., 2011). In rodent models, arsenic suppresses the regeneration of injured 
muscles (Yen et al., 2010), alters pulmonary structure and function in utero by increasing 
the smooth muscle actin in the lung (Lantz et al., 2009), and disrupts the smooth muscle 
integrity around the blood vessels in the heart (Hays et al., 2008) and the thoracic aorta 
(Lim et al., 2011).  
Additionally, rats exposed to arsenic in utero had reduced locomotor activity and 
reductions in limb movements (Chattopadhyay et al., 2002; Rodr  guez et al., 2002).  
Collectively, these results suggest that arsenic acts as a developmental toxicant by 
affecting the development of the musculature and neurons. However, the molecular 
mechanisms responsible these multiple adverse outcomes remain largely unknown. 
Embryonic stem cells (ECSs) are pluripotent cells capable of differentiation into 
multiple cell lineages (Angello et al., 1997; Vanderheyden & Defize, 2003; Wobus & 
Guan, 1998). Since these cells recapitulate gene expression patterns during early 
embryogenesis (Marikawa et al., 2009; Rohwedela et al., 2001), the use of stem cells is a 
promising in vitro model to assess developmental toxicity (Adler et al., 2008; Bal-Price et 
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al., 2010). To this end, it has been shown that exposure of 76 nM arsenic to human stem 
cells caused a significant down regulation of genes indicative of all the three germ layers 
(Flora & Mehta, 2009). Results from mouse embryonic stem cells indicate that 10 mM 
arsenic reduces the formation of embryoid bodies and thereby inhibits cardiac cell 
differentiation (Stummann et al., 2008). Moreover, Tokar and coworkers have 
demonstrated that 5M arsenic can transform human epithelial stem cells into a 
pluripotent cancer stem cell phenotype (Tokar et al., 2010). However, the molecular 
mechanisms responsible for arsenic’s effects during embryogenesis are not well 
understood.  
The Wnt/ β-catenin signaling pathway plays an important role in somite formation 
and neural crest development (Borello et al., 2006; Burstyn-Cohen et al., 2004; Geetha-
Loganathan et al., 2008; Huelsken & Birchmeier, 2001; Schmidt et al., 2008). In stem 
cells, β-catenin regulates self-renewal and cell fate decisions (Ling et al., 2009; Liu et al., 
2008; Lyashenko et al., 2011). For example, β-catenin-deficient mouse stem cells self-
renew rather than differentiate into the three germ layers (Lyashenko et al., 2011), while 
overexpression of β-catenin alone triggers stem cells to differentiate into muscles 
(Petropoulos & Skerjanc, 2002) and neurons differentiation in the WWE6 ES cells (Otero 
et al., 2004).  
Mouse P19 cells are pluripotent embryonal carcinoma cells, which can 
differentiate into multiple cell types under the appropriate conditions (Macpherson & 
McBurney, 1995; McBurney, 1993). Treatment with dimethyl sulfoxide (DMSO) induces 
P19 cells to differentiate into mesoderm and endoderm lineage, while retinoic acid 
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exposed P19 cells differentiate into neuroectoderm lineage (Macpherson & McBurney, 
1995). P19 cells can grow continuously in serum-supplemented media without feeder 
cells, which makes them a good model to investigate the impacts of arsenic exposure on 
cellular differentiation.  The goal of this study was to determine if arsenic reduced 
myogenesis and neurogenesis due to altered Wnt/ β-catenin signaling in embryoid bodies.   
Methods 
P19 cell culture and differentiation 
The mouse embryonal carcinoma P19 cell line (ATCC, Manassas, VA) was 
maintained in -MEM supplemented with 7.5% bovine calf serum (Hyclone, Logan, 
UT), 2.5% fetal bovine serum (Mediatech, Manassas, VA), 1% L-glutamine, and 1% 
penicillin/streptomycin (designated as growth medium) at 37C in a humidified incubator 
containing 5% CO2. Medium renewal was conducted every 48 hours. To induce 
differentiation, P19 cells were aggregated by the hanging drop method (Wang & Yang, 
2008) with some modification. Briefly, P19 cells were trypsinized and suspended in 
differentiation medium (growth medium containing 1%DMSO) with or without 0.5M 
sodium arsenite at a density of 500cells/ 20l or drop. Ninety-six drops of cell suspension 
were placed on the up-turned inner surface of the lid of a 150mm petri dish, which was 
inverted and placed on top of the dish containing 10ml of PBS, and incubated for 2 days 
(day 2).  After 2 days, each individual drop was transferred to a 96-well ultralow 
attachment plate containing 70l of fresh differentiation medium with or without 0.5M 
arsenite. After 3 days (day 5), the embryoid bodies were transferred to a 0.1% gelatin 
coated 48-well plate containing 300l of fresh differentiation medium with or without 
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0.5M sodium arsenite. The medium was renewed every 48 hours until cells were 
harvested.  
qPCR  
P19 cells were cultured with or without 0.5M sodium arsenite as described 
above. When harvesting aggregates on day 5 culture, embryoid bodies from a 96-well 
plate were collected and combined as one replicate (n=3 per group per day), while for day 
9 collection, cells from all wells in a 48-well plate were trypsinized and combined as one 
replicate (n=3 per group per day). Total RNA were extracted using TRI reagent (Sigma-
Aldrich, St. Louis, MO) according to the manufacturer’s instruction. RNA (2μg) was 
reverse transcribed into cDNA and the expression of paired box 3 (Pax3), paired box 7 
(Pax7), myogenic factor 5 (Myf-5), MyoD, myogenin (Mgn), neurogenin-1 (Ngn-1), 
neurogenin-2 (Ngn-2), NeuroD, and Gapdh was quantified by qPCR using SYBR Green 
(SABiosciences, Frederick, MD) and the appropriate primers (Pax3 Forward 5’-CCT 
CTG CCC AAC CAT ATC CG-3’, Reverse: 5’-GAA ATG ACG CAA GGC CGA ATG-
3’; Pax7 Forward: 5’-TCT CCA AGA TTC TGT GCC GAT-3’, Reverse: 5’-CGG GGT 
TCT CTC TCT TAT ACT CC-3’; Myf-5 Forward: 5’-TGC TGT TCT TTC GGG ACC 
AGA CAG G-3’, Reverse: 5’-GGA GAT CCT CAG GAA TGC CAT CCG C-3’; MyoD 
Forward: 5’-ATG CTG GAC AGG CAG TCG AGG C-3’, Reverse: 5’-GCT CTG ATG 
GCA TGA TGG ATT ACA-3’; Mgn Forward: 5’- CCA ACC CAG GAG ATC ATT TG-
3’, Reverse: 5’- ACG ATG GAC GTA AGG GAG TG-3’; Ngn-1: Forward 5’-CCA GCG 
ACA CTG AGT CCT G-3’, Reverse: 5’-CGG GCC ATA GGT GAA GTC TT-3’; Ngn-
2: Forward 5’-AAC TCC ACG TCC CCA TAC AG-3’, Reverse: 5’-GAG GCG CAT 
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AAC GAT GCT TCT-3’). Gapdh was used as the housekeeping gene (Gapdh Forward: 
5’-TGC GAC TTC AAC AGC AAC TC-3’, Reverse: 5’-ATG TAG GCC ATG AGG 
TCC AC-3’). Samples were run in triplicate, and relative gene expression was calculated 
using the comparative threshold (Ct) method (Livak & Schmittgen, 2001).  The 
experiments were replicated at least three times. The results were expressed as mean ± 
SD (standard deviation). Student’s t-test was used to determine significant differences 
(p<0.05) between control and arsenic groups.   
Immunohistochemistry and immunoblotting of differentiated cells 
Embryoid bodies exposed with or without 0.5M sodium arsenite were prepared 
as described above. On day 5, embryoid bodies were plated onto 10-cm tissue culture 
dishes containing 0.1% gelatin coated coverslips. Medium renewal was conducted every 
48 hours until the day for immunofluorescence (n=5 per group per day). Cells were fixed 
with methanol at -20°C for 5 minutes, blocked in 1% bovine serum albumin, 0.1% 
Triton-X100 in PBS, and incubated with the appropriate primary antibody for 1 hour (β-
catenin: 1:100 dilution, Gene Tex # GTX101254; Pax3: 1:200 dilution, Gene Tex 
#GTX100663; MyoD: 1:100 dilution, Santa Cruz # SC-304; Tuj1: 1:100 dilution, 
Millipore # MAB1637; and myosin heavy chain: 50 l of antibody supernatant, DSHB# 
MF20). The secondary antibody (1g/mL) conjugated to Alexa Flour 488 (Invitrogen, 
Carlsbad, CA) was incubated with the cells, which were counterstained with DAPI 
(Invitrogen). Cells were examined by conventional immunofluorescence on a Ti Eclipse 
Inverted Microscope (Nikon, Melville, NY).  
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Protein extractions and immunoblots were performed according to standard 
methods (Dignam et al., 1983; Towbin et al., 1979). When harvesting aggregates on day 
5 culture, embryoid bodies from a 96-well plate were collected and combined as one 
replicate (n=3 per group per day), while for day 12 collection, cells from all wells in a 48-
well plate were trypsinized and combined as one replicate (n=3 per group per day). The 
same primary antibodies were used as for the immunofluorescence (Pax3: 1:1000 
dilution; Tuji: 1:100 dilution;  myosin heavy chain: 1:50 dilution).   Anti-Tbp antibody 
(1:1000 dilution, Abcam#818) and anti-Gapdh antibody (1:1000 dilution, IMGENEX# 
IMG-5019A-1) were used as loading controls. 
 Immunohistochemical analysis of embryoid bodies 
Embryoid bodies at day 2 and day 5 were exposed to 0 or 0.5M  arsenite as 
described above. For day 2 collection, ninety-six drops of cell suspension were harvested 
from a 150mm petri dish combined as one replicate (n=3 per group per day), while for 
embryoid bodies on day 5 culture, aggregates from a 96-well plate were collected and 
combined as one replicate (n=3 per group per day). Once harvested, embryoid bodies 
were fixed for 24 hours in 10% neutral buffered formalin, dehydrated in graded ethanol, 
processed, and embedded in paraffin. Sections (5m) were placed on slides, 
deparaffinized with xylene, and rehydrated in graded ethanol solutions. β-catenin and 
Pax3 staining was carried out in a dark humid chamber for 1 hour, using anti-β-catenin 
antibody (1:100 dilution, Gene Tex # GTX101254) and anti-Pax3 antibody (1:200 
dilution, Gene Tex #GTX100663). The secondary antibody (1g/mL) conjugated to 
Alexa Flour 488 (Invitrogen, Carlsbad, CA) was incubated with the slides, which were 
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counterstained with DAPI (Invitrogen). Slides were examined by conventional 
immunofluorescence on a Ti Eclipse Inverted Microscope (Nikon, Melville, NY).  
Results 
Arsenic represses skeletal muscles and neuronal differentiation in P19 cells  
To examine the developmental effects of arsenic exposure on stem cell 
differentiation, P19 cell aggregates (embryoid bodies, EBs) were formed in hanging drop 
culture containing 1% DMSO with or without 0.5M sodium arsenite. According to our 
morphological observations, endoderm-like smooth muscles were observed in the 
differentiating outgrowths from the control embryoid bodies on day 7 (Fig. 1A). Later on, 
myoblasts and myotubes, representing about 15% of the total cells, could be identified at 
day 9 (Fig. 1C) and day 12 (Fig. 1E), respectively. These results are consistent with 
previous reports (McBurney, 1993; Skerjanc, 1999). Interestingly, in our experiments, 
neurons were also formed at days 9 and 12 (Fig.1E and 1G), representing 30-40% of the 
total cells by day 12.  The morphology of embryoid bodies exposed to 0.5M arsenic was 
the same as that from the control groups (Fig. 1B). However, the formation of smooth 
cells, skeletal muscles, and neurons were significantly reduced (less than 5% of total 
cells). Instead, the majority of differentiated cells retained the typical epithelial cell-like 
morphology (~80% of total cells, Fig. 1D, F, and H).  A final ~10 to 15% of the total cell 
numbers in the arsenic-exposed group remained as embryoid bodies, without any sign of 
differentiation out from the embryoid body (data not shown).   
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Arsenic represses β-catenin expression in the differentiating embryoid bodies 
Since Wnt/ β-catenin signaling plays an important role in the induction of early 
myogenesis and neurogenesis (Marikawa, et al., 2009; Petropoulos & Skerjanc, 2002; 
Tang et al., 2002), we next asked whether the repressed skeletal muscle and neuronal 
differentiation in the arsenic-exposed P19-derived embyroid bodies was due to altered 
Wnt/β-catenin signaling. Immunofluorescence was conducted to examine the expression 
of β-catenin in embryoid bodies during days 2 and days 5 of aggregation. Results from 
our control groups indicate that β-catenin was highly expressed in day 2 and then 
expression levels were reduced in day 5 (Fig 2A and C). However, in arsenic-treated P19 
cells, the expression of β-catenin in the embryoid bodies was much lower than controls at 
both day 2 and day 5 (Fig. 2B and D).  
Arsenic represses Pax 3 expression ay the edges of embryoid bodies 
During embryogenesis, Pax3 is an essential transcription factor that regulates 
skeletal muscle and neuronal differentiation by targeting myogenic and neurogenic 
transcription factors (Ichi et al., 2011; Lagha et al., 2008; Ridgeway et al., 2000). 
Moreover, it has been shown that Wnt/ β-catenin activates Pax3 expression in P19 cells 
(Marikawa, et al., 2009; Petropoulos & Skerjanc, 2002). To this end, we examined 
whether repressed β-catenin expression in arsenic-exposed embryoid bodies lead to the 
reduction of Pax3 expression.  In control cells, Pax3 was highly expressed in the 
embryoid bodies on day 2 and day 5 (Fig. 3A) and continued to express in the cells 
differentiating out from embryoid bodies on day 9 (Fig 3A). However, in arsenic-exposed 
groups, Pax3 expression was repressed in the embryoid bodies on day 2 and day 5. And 
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most importantly, Pax3 protein was almost absent in the day 9 cells (Fig. 3A). Examining 
Pax3 mRNA levels by qPCR corroborated the immunofluorescence, showing a 
significant reduction in Pax3 transcripts by 2- to 2.7-fold in the arsenic-treated groups on 
day 5 and day 9, respectively (Fig. 3B). Additionally, immunoblotting showed a 
reduction of Pax3 protein expression in the nuclear fraction of the day 5 arsenic-exposed 
embryoid bodies (Fig. 3C).   
 Arsenic represses skeletal muscle differentiation through the repressed myogenic 
regulatory factors (MRFs)  
The development of skeletal muscle is regulated by several myogenic 
transcription factors, such as Myf5, Myo D, and myogenin (Yokoyama & Asahara, 
2011). In myogenesis, Myf5 and MyoD are early transcription factors that direct the 
differentiation of muscle progenitors to myoblasts. Later on, both Myf5 and MyoD 
regulate the expression of myogenin, which induces terminal differentiation by 
converting myoblasts into myotubes (Carvajal & Rigby, 2010; Gianakopoulos et al., 
2011; Yokoyama & Asahara, 2011). Therefore, to examine whether the repressed muscle 
differentiation by arsenic exposure was due to the reduction of the essential myogenic 
transcription factors, the expression Myf5, MyoD, and myogenin from P19 cells exposed 
with or without arsenic during differentiation was determined. In the control groups, 
Myf5 mRNA transcripts were expressed on day 5 and then were diminished on day 9, 
MyoD was present on day 5 and its expression was increased by 3-fold on day 9 in the 
control group. The expression of myogenin was barely detectable on day 5, but it was 
induced by 150-fold on day 9, as myogenin is needed for terminal muscle differentiation. 
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In the arsenic-exposed differentiating P19 cells, the expression of Myf5, MyoD, and 
myogenin in both of the embryoid bodies at day 5 and in the differentiating cells on Day 
9 was significantly repressed (Fig. 4A).  The transcript results were also seen in protein 
expression, as immunofluorescence indicated that MyoD expression in the differentiated 
embryoid bodies was highly repressed in the arsenic groups on day 9 (Fig. 4B). The 
reductions in myogenin transcription factor expression resulted in suppressed muscle 
formation, as indicated by the reductions in myosin heavy chain expression on day 12 
(Fig. 4C and D).  
Arsenic represses neuronal differentiation through the repressed neurogenic 
transcription factors 
Neurogenin1, neurogenin 2, and NeuroD are three important transcription factors 
in neuronal differentiation (Howard, 2005; E. Kim et al., 2011). In mammalians, both 
neurogenin 1 and neurogenin 2 are expressed in neuronal precursors (neuroblasts) in 
neurogenesis (Cau et al., 2002; Kim, et al., 2011; Ma et al., 1999), whereas the 
expression of NeuroD, promotes neuronal fate determination and differentiation (Cherry 
et al., 2011; Howard, 2005; Ohsawa & Kageyama, 2008). The reduced neuronal 
differentiation in arsenic-exposed P19 cells is due to a significant reduction in neurogenin 
1, neurogenin 2 and NeuroD transcripts on day 5 and day 9 (Fig. 5A), which results in 
reduced protein expression of the neuronal-specific tubulin Tuj1 on day 12 (Fig. 5B and 
C).  
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Discussion  
The results from the present study using P19 stem cells illustrate that sodium 
arsenite suppresses skeletal muscle and neuronal differentiation through repressed β-
catenin expression.  Lowered -catenin levels leads to reductions in the specific 
transcription factors needed to convert stem cells into neurons and skeletal myotubes.  To 
the best of our knowledge, this is the first study to illustrate that low levels of arsenic can 
alter the Wnt/β-catenin pathway and repress stem cell differentiation.  
To induce P19 differentiation, DMSO has long been used as a chemical reagent 
for the induction of mesoderm and endoderm lineages (McBurney, 1993; Vanderheyden 
& Defize, 2003). In this study, surprisingly, we found that DMSO could also induce 
neuroectoderm lineage in P19 cells. Although reports have demonstrated that DMSO can 
induce neuronal differentiation in neuroblastoma cells (Kimhi et al., 1976; Oh et al., 
2006), this has not been seen in P19 cells. Reports have indicated that, in the absence of 
retinoic acid, overexpressing neurogenin 1 in P19 cells induces neuronal formation by 
up-regulating NeuroD expression, (Kim et al., 2004).  In the present study, both 
neurogenin 1 and 2 transcripts were seen during embyroid body formation.  In the 
differentiation and outgrowth period, their expression increased. Neurogenin by 37-fold 
and 10-fold, respectively expression induces NeuroD (Howard, 2005; Kim, et al., 2004; 
Osório et al., 2010). NeuroD transcript was barely detectable in the embryoid body, but 
during the differentiation period, its expression was highly increased, thus leading to 
neuronal differentiation in P19 cells without any chemical induction. Previous studies 
have also demonstrated that by co-culturing DMSO-exposed P19 embryoid bodies with 
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the primitive streak mesoderm-like cell line GCLB, neuronal lineage could be induced 
successfully without retinoic acid (Pruitt, 1994). The author of that study hypothesized 
that the neuronal differentiation of P19 cells was due to the synergistic action of a Pax3 
signal from GCLB cells and the DMSO treatment (Pruitt, 1994). It is known that Pax3 
promotes sensory neuron differentiation in mammalians (Baker et al., 2002; Ichi, et al., 
2011; Koblar et al., 1999) and Pax3 can be induced when P19 cells treated with DMSO 
(Petropoulos et al., 2004; Petropoulos & Skerjanc, 2002). Therefore, it is reasonable to 
expect that DMSO-induced Pax3 can trigger neurogenin expression in P19 cells.  
Our immunofluorescence analysis of sectioned embryoid bodies indicates that β-
catenin was expressed on day 2 in the control groups. On day 5, the β-catenin levels were 
greatly reduced, but remained detectable. Such temporal patterns of β-catenin expression 
are consistent with previous reports using P19 cells. For example, it has been shown that 
the level of Wnt/β-catenin reached maximum on day 2 of P19 cell differentiation, during 
mesoderm formation, and then started to decrease on day 3 (Marikawa, et al., 2009). 
Moreover, Paige and co-workers have observed that Wnt/β-catenin was expressed on day 
2 and then decreased thereafter during cardiac differentiation in human stem cells (Paige 
et al., 2010). Indeed, in mice, it has been shown that β-catenin is necessary for embryonic 
development but no longer required for the fetal development, such as the differentiation 
of myoblasts (Hutcheson et al., 2009). In the arsenic-exposed embryoid bodies, however, 
β-catenin levels were repressed on day 2 and nearly undetectable on day 5. Such 
repressed β-catenin indicates that Wnt signaling was reduced in the early stage of 
embryoid body development by arsenite. This may be the initial regulatory mechanism 
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responsible for the repressed skeletal muscle and neuronal differentiation on day 9 and 
day 12 after arsenic exposure. Indeed, it has been shown that β-catenin can directly 
activate Myf5, as two β-catenin responsive elements in Myf5 promoter are essential for 
mouse myotomal development (Borello, et al., 2006). Moreover, β-catenin also enhances 
neurogenesis in neural progenitors through the induction of neurogenin-2 (Hirsch et al., 
2007). Our qPCR also shows a significant reduction of Myf5 and Neurogenin-2 
expression on day 5 and day 9 upon arsenic exposure.  
Recently, altered Wnt/ β-catenin signaling has been reported after arsenic 
exposure. For example, arsenic trioxide (As2O3) reduces cytoplasmic β-catenin 
accumulation and induces apoptosis in human primary myeloma cells (Zhou et al., 2008), 
while arsenic trichloride (AsCl3)-induced reactive oxygen species (ROS) formation 
promotes cell transformation and tumorigenesis through the induction of Wnt/ β-catenin 
signaling in human colorectal adenocarcinoma DLD1 cells (Zhang et al., 2011). Funato 
and co-workers have found, using HEK293 cells and Xenopus experiments, that ROS-
mediated β-catenin reduction can be regulated by overexpressing nucleoredoxin, which is 
a thioredoxin family member (Funato et al., 2006; Funato & Miki, 2010). Since arsenic 
toxicity has been related to the induction of ROS (Garcia-Chavez et al., 2007; Piao et al., 
2005; States et al., 2009), and thioredoxin and nucleoredoxin could act as antioxidant 
enzymes to protect oxidative stress (Miao & St Clair, 2009; Patenaude et al., 2005), 
arsenic-induced reactive oxygen species may play a role in the reduction of β-catenin 
expression in P19 cells.  
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During differentiation, β-catenin-signaling triggers myogenesis through Pax3 and 
myogenic regulatory factors, such as Mrf5 and MyoD (Petropoulos & Skerjanc, 2002; 
Ridgeway et al., 2000). Additionally, β-catenin also promotes sensory neuron 
differentiation by up-regulating Pax3, (Burstyn-Cohen et al., 2004; Tang et al., 2002). Of 
these transcription factors, Pax3 is common to both skeletal muscle and sensory neuron 
differentiation (Howard, 2005; Lassiter et al., 2010; Messina & Cossu, 2009). Therefore, 
its spatial and temporal expression was examined. As expected, Pax3 expression was 
lower in the arsenite-exposed embryoid bodies on both day 2 and day 5, likely due to the 
reduced -catenin levels. It is interesting that the spatial expression of Pax3 differed 
between control and arsenite-exposed cells.  In control cells, Pax3 is highly expressed at 
the edges of the embryoid bodies and is later expressed in the differentiating cells on day 
9.  In the arsenic-exposed cells, Pax3 is expressed in the interior of the embyroid body, 
but its expression is extremely low at the edges of embryoid bodies. By day 9, Pax3 
expression is almost absent in the differentiated regions from arsenic-exposed embryoid 
bodies. In contrast, on day 9, Pax3 is expressed in the differentiated and differentiating 
outgrowing cells where the skeletal myotubes and neurons are formed on Day 9 and Day 
12.  
In the nervous system, Pax3 upregulates Neurogenin 2 (Ichi et al., 2011; Lassiter 
et al., 2010; Nakazaki et al., 2008), which is a preneuronal gene that plays a key role in 
the specification of neuronal subtypes, neural crest development, and sensory 
neurogenesis (Baker, et al., 2002; Dude et al., 2009; Howard, 2005; Nakazaki, et al., 
2008).  In skeletal muscle progenitors, Pax3 upregulates Myf5, MyoD, and myogenin 
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(Buckingham, 2007; Gianakopoulos et al., 2011; Ridgeway & Skerjanc, 2001). Indeed, 
these key transcription factors for muscle and neuronal differentiation were also 
repressed by arsenic exposure in this study, as evidenced by qPCR and 
immunofluorescence. Moreover, Pax7 transcripts, which have been suggested to play a 
key role in muscle and neuronal cells fate determination in mice (Jostes et al., 1990; 
Murdoch et al., 2010; Ziman et al., 2001), also is reduced by 7-fold after arsenic exposure 
on day 9 of embryoid body differentiation (data not shown).  
In conclusion, our results indicate that 0.5μM sodium arsenite suppresses skeletal 
muscle and neuronal differentiation from P19 mouse embryonic stem cells due to 
reductions in myogenic and neurogenic transcription factors expression. The regulatory 
mechanism that may be responsible for these reductions after arsenic exposure is 
repressed Wnt/ β-catenin signaling during the early embryogenesis stage. P19 stem cells 
appear to be a useful model to determine the mechanisms by which toxicants impact 
embryogenesis.  
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Fig. 4.1 Arsenic represses skeletal muscles and neuronal differentiation in P19 cells.  
P19 cells were aggregated as hanging drop cultures in the presence or absence of 
0.5M sodium arsenite for 5 days (A and B), then transferred to gelatin-coated plates. On 
day 5 
day 7 
day 9 
day 12 
20 µm 
A B 
C D 
E 
G 
F 
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Day 7, myoblast-like cells were observed around the embryoid bodies in the control 
groups (C), while on Days 9 and Day 12, myoblasts, myotubes, and neurons could be 
identified (E and G). Arrows show myotubes and arrowheads indicate the differentiated 
neurons. In arsenic-exposed groups, the P19-like cells were dominant in the outgrowth 
area on Days 7, 9, and 12 (D, F, and H). Pictures are representative examples from 198 
independent embryoid bodies per time point per group. 
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Fig 4.2 Arsenic represses β-catenin expression in the differentiating embryoid bodies 
P19 cells were aggregated as hanging drop cultures containing 1% DMSO for 2 
and 5 days with (A and C) or without (B and D) 0.5M sodium arsenite. Embryoid 
bodies were harvested and embedded with paraffin, and β-catenin expression was 
examined by immunofluorescence. Pictures are representative examples from 198 
embryoid bodies per time point per group. 
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Fig 4.3 Arsenic represses Pax 3 expression at the edges of embryoid bodies 
P19 cells were aggregated in the presence or absence of 0.5M sodium arsenite for 5 
days, then transferred to gelatin-coated plates for 4 days (Day 9) with or without 0.5M 
Pax3 DAPI Merge Pax3 DAPI Merge 
Control  0.5M As 
day 2 
day 5 
day 9 
C. 
EB EB EB EB EB EB 
20 µm 
A. 
B. 
0.5µM As   Control 
* 
* 
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sodium arsenite to examine Pax3 expression by immunofluorescence (A). Arrows 
indicates the exterior regions of embryoid bodies with induced Pax3 expression. Dashed 
lines indicate the location of an embryoid body (EB). Pictures are representative 
examples from 198 independent embryoid bodies per time point per group. Pax3 mRNA 
expression on Day 5 and Day 9 was quantified by qPCR. Each sample was run in 
triplicate (n=3, 96 embryoid bodies/ sample/day/group) and results were normalized to 
GAPDH and expressed as normalized fold-change to relative to P19 5 days control cells. 
Statistical differences (*) were determined by Student’s t-test (p<0.05) (B). Pax3 protein 
expression in the nuclear fraction of embryoid bodies exposed with or without 0.5M 
arsenic for 5 days (Day 5) was quantified by immmunoblotting (C). 
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Fig 4.4 Arsenic represses skeletal muscle differentiation through the repressed 
myogenic regulatory factors (MRFs) 
Myf5, MyoD, and myogenin mRNA expression in cells derived from embryoid 
bodies day 5 and day 9 was quantified by qPCR. Each sample was run in triplicate (n=3), 
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results were normalized to Gapdh, and are expressed as normalized fold-change to 
relative to day 5 control cells. Statistical differences (*) were determined by Student’s t-
test (p<0.05) (A). Differentiated cells from embryoid bodies exposed with or without 
0.5M arsenic on day 9 (B) and day 12 (C) were fixed, and MyoD (day 9) and myosin 
heavy chain (day 12) expression was examined by immunofluorescence. Dashed lines 
indicate the location of an embryoid body (EB). Pictures are representative examples 
from 198 independent embryoid bodies/time point/group. Myosin heavy chain protein 
expression was examined by immmunoblotting, using embryoid bodies exposed with or 
without 0.5M arsenic on Day 12 (D). 
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Fig 4.5 Arsenic inhibits neuronal differentiation by repressing neurogenic 
transcription factors 
Neurogenin1, Neurogenin 2, and NeuroD mRNA expression from embryoid 
bodies exposed with or without 0.5M arsenic for 5 days and 9 days were determined by 
qPCR (A). Each sample was run in triplicate (n=3), results were normalized to Gapdh, 
and expressed as normalized fold-change to relative to day 5 control cells. Statistical 
differences (*) were determined by Student’s t-test (p<0.05). Differentiated control cells 
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and cells exposed to 0.5M arsenite were fixed on day 12, and Tuj1 expression was 
examined by immunofluorescence (B). Pictures are representative examples from 198 
independent embryoid bodies/time point/group. Tuj1 protein expression was quantified 
by immmunoblotting, using embryoid bodies exposed with or without 0.5M arsenic on 
day 12 (C). 
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Fig 4.6 Model of the transcription factor cascade that inhibits skeletal myotube and 
sensory neuron formation after arsenite exposure.  
During P19 aggregation, β-catenin expression was repressed by arsenic exposure 
on day 2.  The repressed β-catenin leads to the reduction of Pax3, which plays an 
important role in specification of muscle and neuronal precursors. The reduced muscle 
and neuronal precursors development by arsenic exposure was supported by the repressed 
Myf5, MyoD, Neurogenin 1, and Neurogenin 2 expression on day 5 and day 9.  The 
expression of myogenin and NeuroD, both could regulate terminal skeletal and neuronal 
differentiation (Howard, 2005; Yokoyama & Asahara, 2011), were repressed by arsenic 
on day 9. Thereby leading to the suppressed formation of skeletal muscles and neurons 
on day 12. 
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CHAPTER FIVE 
CONCLUSION 
The molecular mechanisms that regulate the arsenic-induced developmental 
toxicity are largely unclear and likely are multi-factorial. To this end, both mouse C2C12 
myoblast cells and P19 stem cells were used in this study to investigate the 
developmental toxicity of arsenic. Our results from Chapter 2 indicate that exposure of 20 
nM sodium arsenite to C2C12 myoblast cells could delay their differentiation through the 
reduction of myogenin expression. The repressed myogenin expression was due to altered 
DNA methylation patterns on the myogenin promoter and the reduced expression of 
myogenic transcription factor, Mef2. Chapter 3 further demonstrates that arsenic 
exposure to C2C12 cells could induce heterochromatin formation on the proximal 
myogenin promoter, reduce Igf-1 expression, and enhance the expression of muscle 
repressor, Ezh2. These altered mechanisms co-contribute to the reduction of myogenin, 
thereby leading to the delayed muscle differentiation following arsenic exposure. In 
chapter 4, arsenic’s effects on early development were examined, using mouse P19 stem 
cells as a model. Our results indicate that arsenic has the ability to inhibit myogenesis and 
neurogenesis through the reduction of essential transcription factors in the Wnt signaling 
pathway.   
Indeed, results from this study indicate that arsenic has the ability to silence gene 
expression by simply altering DNA methylation patterns on a target gene’s promoter 
region or induce the formation of closed chromatin on critical promoter regions, where 
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can be interacted with the basal transcription complexes, such as RNA Pol II and TATA 
box binding proteins. In addition, arsenic could also repress gene expression via 
synergistically regulates the expression of growth factors (Igf-1 and myostatin), the 
Polycomb Ezh2 methytransferase enzyme, and the enhancer protein (Mef2). Moreover, 
arsenic could affect gene expression through signaling transduction. For instance, through 
the altered Wnt/ β-catenin signaling pathway, arsenic represses essential myogenic- and 
neurogenic-transcription factors, thereby leading to inhibited myogenesis and 
neurogenesis. Taken together, it appears that arsenic exposure could affect cellular 
differentiation via targeting cell cycles, such as the Igf-1 mediated PI3K pathway, or by 
epigenetic regulatory mechanisms 
Data from the 2003-2008 National Health and Nutrition Examination Survey 
(NHANES) indicates that the median urinary arsenic concentration in the U. S. adults is 
8.3 μg/L (Jones et al., 2011). Additionally, in an area of Argentina with 200ppb in 
drinking water, arsenic levels from placentas and cord blood from babies were 34μg/kg 
and 9 μg/L, respectively (Concha et al., 1998). Our results indicate that 2.7 μg/L arsenic  
(equivalent to a 20 ppb exposure) could delay muscle differentiation and reduce muscle 
fibers formation. In Mexico, school-aged children exposed to 117-1392 ppm arsenic in 
their drinking water have abnormal neurophysiological behavior, such as a lower IQ 
score and poor verbal learning and memory. Their hair arsenic levels averaged 40 ppb or 
5.4 μg/kg (Caldero et al., 2001; Diazbarriga et al., 1993). Our P19 stem cell model shows 
that both neurogenesis and myogenesis are inhibited upon 65 g/L arsenic exposure. 
Because arsenic levels in cord blood and placentas can be used as surrogates for exposure 
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levels for a developing embryo, which were 9 μg/L and 34 μg/kg, respectively. Our P19 
cells exposed to 65 g/L arsenic is similar to that measured in these epidemiological 
studies. However, there are some limitations when stem cells and attempting to compare 
their exposure to that of a fetus. For example, the cultured stem cells may not behave in a 
similar manner like inner mass cells within a fetus, that may not have the same metabolic 
capabilities to methylate and detoxify arsenic, and although we know what concentrations 
of arsenic the embryoid body was exposed to, we do not know how much is actually in 
the embryoid body. However, this study can help elucidate the mechanisms of how 
environmental realistic arsenic exposure impacts early development. 
Arsenic is present in water systems around the world, but the mechanisms by 
which arsenic causes health effects are still not well understood. Because epidemiological 
studies indicate that long-term exposure to arsenic can result in cancer and other adverse 
outcomes in skeletal and neuronal development (Fig 1.1 and 1.2), the United States 
Environmental Protection Agency (EPA) reduced the allowable concentration of arsenic 
in drinking water from 50 ppb to 10 ppb by 2006 (EPA, 2001). However, the tighter 
standards have been questioned, because most of the epidemiological studies were 
conducted in Bangladesh, Chile, Taiwan, and India, where the arsenic concentrations are 
generally higher than that in the United States (Chen et al., 1988; Rahan et al., 2007; 
Smith et al., 1998). This study supports the EPA’s tighter standards about the regulations 
of arsenic in public drinking water systems. This study demonstrates that exposure of 
20nM arsenic or 2.6ppb arsenic, which is below current drinking water standard of 
10ppb, can result in the delayed muscle differentiation and lead to improper organization 
 144 
of muscle fibers. Since improper organized muscle fibers may ultimately cause abnormal 
physiological outcomes on organism, it is reasonable to ask whether the drinking water 
standard for arsenic is protective of public health, especially for the aspects of fetal 
development.  To this end, Canada has reevaluated arsenic concentration in drinking 
water. The proposed allowable arsenic in drinking water is 5 ppb (Kapaj et al., 2006).   
To date, the risk assessment of arsenic exposure at low levels is limited, due to a 
lack of data (Gibb et al., 2011). To extrapolate risk of low-dose arsenic exposure by using 
traditional whole-animal experiments is sometimes not feasible. For example, animals are 
often treated with high tolerable doses so that hazards can be identified (van Vliet, 2011). 
Such high concentrations are very different from real-life environments, because humans 
are exposed to low levels of environmental chemicals, such as arsenic in drinking water. 
Therefore, a mouse P19 stem cell line was used in this study to evaluate the impacts of 
low-level arsenic exposure on cellular differentiation. Results from 500 nM arsenic 
exposure indicate arsenic inhibits myogenesis and neurogenesis through the repressed 
essential myogenic- and neurogenic-transcription factors, caused by the reduction of 
Wnt/ β-catenin signaling pathway during early embryogenesis. To our knowledge, this is 
the first report that uses stem cell-based assays to examine the adverse developmental 
effects of low-level arsenic exposure in the embryogenesis. This arsenic-exposed P19 
stem model may, at least in part, give us insight into what has been observed from the 
epidemiological studies that show the arsenic-mediated adverse developmental effects 
during pregnancy. Most importantly, by combination of other approaches, such as -omics 
analysis, assessments of cytotoxic effects on undifferentiated/differentiated P19 cells, and 
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IC50 analysis of three germ layers, this P19 model has potential for the comprehensive 
evaluation of arsenic-mediated developmental toxicity in the future.     
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